WO1999049901A1 - Water soluble paclitaxel derivatives - Google Patents
Water soluble paclitaxel derivatives Download PDFInfo
- Publication number
- WO1999049901A1 WO1999049901A1 PCT/US1999/006870 US9906870W WO9949901A1 WO 1999049901 A1 WO1999049901 A1 WO 1999049901A1 US 9906870 W US9906870 W US 9906870W WO 9949901 A1 WO9949901 A1 WO 9949901A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- paclitaxel
- txl
- tumor
- poly
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
- A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/06—Polycondensates having nitrogen-containing heterocyclic rings in the main chain of the macromolecule
- C08G73/10—Polyimides; Polyester-imides; Polyamide-imides; Polyamide acids or similar polyimide precursors
- C08G73/1092—Polysuccinimides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/606—Coatings
Definitions
- the present invention relates generally to the fields of pharmaceutical compositions to be used in the treatment of cancer, autoimmune diseases and restenosis.
- the present invention also relates to the field of pharmaceutical preparations of anticancer agents such as paclitaxel (TaxolTM) and docetaxel (Taxotere), in particular making paclitaxel water soluble by conjugating the drug to water soluble moieties.
- anticancer agents such as paclitaxel (TaxolTM) and docetaxel (Taxotere)
- Paclitaxel an anti-micro tubule agent extracted from the needles and bark of the Pacific yew tree, Taxus brevifolia, has shown a remarkable anti-neoplastic effect in human cancer in Phase I studies and early Phase II and III trials (Horwitz et ⁇ l, 1993). This has been reported primarily in advanced ovarian and breast cancer. Significant activity has been documented in small-cell and non-small cell lung cancer, head and neck cancers, and in metastatic melanoma. However, a major difficulty in the development of paclitaxel for clinical trial use has been its insolubility in water.
- Docetaxel is semisynthetically produced from 10-deacetyl baccatin III, a noncytotoxic precursor extracted from the needles of T ⁇ xus b ⁇ cc ⁇ t ⁇ and esterified with a chemically synthesized side chain (Cortes and Pazdur, 1995). Narious cancer cell lines, including breast, lung, ovarian, and colorectal cancers and melanomas have been shown to be responsive to docetaxel. In clinical trials, docetaxel has been used to achieve complete or partial responses in breast, ovarian, head and neck cancers, .and malignant melanoma. 2
- Paclitaxel is typically formulated as a concentrated solution containing paclitaxel, 6 mg per milliliter of Cremophor EL (polyoxyethylated castor oil) and dehydrated alcohol (50% v/v) and must be further diluted before administration (Goldspiel, 1994).
- Paclitaxel (TaxolTM) has shown significant activity in human cancers, including breast, ovarian, non-small cell lung, and head and neck cancers (Rowinsky and Donehower, 1995). It has also shown significant activity in patients with advanced breast cancer who had been treated with multiple chemotherapeutic agents (Foa et al., 1994). As with most chemotherapeutic agents, however, the maximum tolerated dose of paclitaxel is limited by toxicity.
- paclitaxel's major toxic effect at doses of 100-250 mg/m is granulocytopenia (Holmes et al., 1995); symptomatic peripheral neuropathy is its principal nonhematologic toxicity (Rowinsky et al., 1993).
- Cremophor EL necessary to deliver the required doses of paclitaxel is significantly higher tlran that administered with any other drug that is formulated in Cremophor.
- Several toxic effects have been attributed to Cremophor, including vasodilatation, dyspnea, and hypotension. This vehicle has also been shown to cause serious hypersensitivity in laboratory animals and humans (Weiss et al.,
- paclitaxel that can be administered to mice by i.v. bolus injection is dictated by the acute lethal toxicity of the Cremophor vehicle
- Cremophor EL a surfactant
- Cremophor EL a surfactant
- DEHP di(2-ethylhexyl)phthalate
- This preparation of paclitaxel is also shown to foim particulate matter over time and thus filtration is necessary during administration (Goldspiel, 1994). Therefore, special provisions are necessary for the preparation and administration of paclitaxel solutions to ensure safe drug delivery to patients, and these provisions inevitably lead to higher costs.
- protaxols novel type of prodrug termed "protaxols”. These compounds possess greater aqueous solubility and are converted to paclitaxel as the active drug through .an intr.amolecul.ar hydrolysis mechanism. However, no in vivo data on the antitumor activity of protaxols are yet available. Greenwald et al. reported the synthesis of highly water-soluble 2' and 7-polyethylene glycol esters of paclitaxel (Greenwald et al, 1994).
- PEG polyethylene glycol
- paclitaxel therapy Another obstacle to the widespread use of paclitaxel is the limited resources from which paclitaxel is produced, causing paclitaxel therapy to be expensive. A course of treatment may cost several thousand dollars, for example. There is the added disadvantage that not all tumors respond to paclitaxel therapy, and this may be due to the paclitaxel not getting into the tumor. There is an immediate need, therefore, for effective formulations of paclitaxel and related drugs that are water soluble with long serum half lives for treatment of tumors, autoimmune diseases such as rheumatoid arthritis, as well as for the prevention of restenosis of vessels subject to traumas such as angioplasty and stenting.
- compositions comprising a chemotherapeutic and/or antiangiogenic drug, such as paclitaxel, docetaxel, or other taxoid conjugated to a water soluble polymer such as a water soluble polyamino acid, or to a water soluble metal chelator. It is a further embodiment of the present invention that a composition comprising a conjugate of paclitaxel and poly-glutamic acid has surprising antitumor activity in animal models, and further that this composition is demonstrated herein to be a new species of taxane that has pharmaceutical properties different from that of paclitaxel.
- compositions are shown herein to be surprisingly effective as antitumor agents against exemplary tumor models, and are expected to be at least as effective as paclitaxel, docetaxel, or other taxoid against any of the diseases or conditions for wliich taxanes or taxoids are known to be effective.
- the compositions of the invention provide water soluble taxoids to overcome the drawbacks associated with the insolubility of the drugs themselves, .and also provide the advantages of improved efficacy and controlled release so that tumors .are shown herein to be eradicated in animal models after a single intravenous administration, as well as providing a novel taxane.
- Poly-(l-glutamic acid) conjugated paclitaxel is shown in the 5 examples hereinbelow to have a novel drug activity, in addition to having improved the delivery to the tumor and providing a controlled release.
- the methods described herein could also be used to make water soluble polymer conjugates of other therapeutic agents, contrast agents and drugs, including paclitaxel, tamoxifen, Taxotere, etopside, teniposide, fludarab ⁇ ne, doxorubicin, daunomycin, emodin, 5-fluorouracil, FUDR, estradiol, camptothecin, retinoids, verapamil, epothilones cyclosporin, and other taxoids.
- those agents with a free hydroxyl group would be conjugated to the polymers by similar chemical reactions as described herein for paclitaxel.
- conjugated to a water soluble polymer means the covalent bonding of the drug to the polymer or chelator.
- the water soluble conjugates of the present invention may be administered in conjunction with other drugs, including other anti-tumor or anti-cancer drugs. Such combinations are .known in the art.
- the water soluble paclitaxel, docetaxel, or other taxoid, or in preferred embodiments the poly-(l- glut.amic) acid conjugated paclitaxel (PG-TXL), of the present invention may, in certain types of treatment, be combined with a platinum drug, .an antitumor agent such as doxorubicin or daunorubicin, for example, or other drugs that are used in combination with TaxolTM or combined with external or internal irradiation, that is to say, radiation administered by an external radiation source, or administered systemically, for ex.ample, by injection or ingestion of radioactive materials, such as a radioisotope containing formulation.
- a polymer-drug conjugate that would normally remain in the vasculature may selectively leak from blood vessels into tumors, resulting in tumor accumulation of active therapeutic drug.
- the water soluble polymers such as, in preferred embodiments PG-TXL, may have pharmacological properties different from non- conjugated drugs (i.e. paclitaxel). Additionally, polymer-drug conjugates may act as drug depots for sustained release, producing prolonged drug exposure to tumor cells.
- water soluble polymers e.g., water soluble polyamino acids
- water soluble polymers may be used to stabilize drugs, as well as to solubilize otherwise insoluble compounds.
- synthetic and natural polymers have been examined for their ability to enhance tumor-specific drug delivery (Kopecek, 1990, Maeda and Matsumura, 1989).
- SMANCS Session Management System
- HPMA-Dox in the United Kingdom
- a taxoid is understood to mean those compounds that include paclitaxels and docetaxel, and other chemicals that have the taxane skeleton (Cortes and Pazdur, 1995), and may be isolated from natural sources such as the Yew tree, or from cell culture, or chemically synthesized molecules, .and a preferred taxane is a chemical of the general chemical formula, C 7 H 5I NO I4 , including [2aR- [2a ⁇ ,4 ⁇ ,4 ⁇ ,6 ⁇ ,9 ⁇ ( ⁇ R* , ⁇ S *), 11 ⁇ , 12 ⁇ , 12a ⁇ , 12b ⁇ ,]]- ⁇ -(Benzoylamino)- ⁇ - hydroxyben-zene prop.anoic acid 6, 12b,bis(acetyloxy)-12-(benzoyloxy)- 2a,3,4,4a,5,6,9,10,l 1, 12,12a,12b-dodecahydro-4,l l-dihydroxy-4a,8,13,13- tetra
- paclitaxel and docetaxel are each more effective than the other against certain types of tumors, .and that in the practice of the present invention, those tumors 7 that are more susceptible to a particular taxoid would be treated with that water soluble taxoid or taxane conjugate.
- the composition may further comprise a chelated metal ion.
- the chelated metal ion of the present invention may be an ionic fof. m of any one of aluminum, boron, calcium, chromium, cobalt, copper, dysprosium, erbium, europium, gadolinium, gallium, germanium, holmium, indium, iridium, iron, magnesium, manganese, nickel, platinum, rhenium, rubidium, ruthenium, samarium, sodium, technetium, thallium, tin, yttrium or zinc.
- the chelated metal ion will be a radionuclide, i.e. a radioactive isotope of one of the listed metals.
- Preferred radionuclides include, but are not limited to 67 Ga, 68 Ga, l ⁇ In, 99m Tc, 90 Y, 114m Sn and ,93m Pt.
- Preferred water soluble chelators to be used in the practice of the present invention include, but are not limited to, diethylenetri-aminepentaacetic acid (DTP A), ethylenediaminetetraacetic acid (EDTA), 1 ,4,7,10-tetraazacyclododecane- N,N',N",N'"-tetraacetate (DOTA), tetr.aazacyclotetradecane-N 5 N',N"N'"-tetraacetic acid (TETA), hydroxyethylidene diphosphonate (HEDP), dimercaptosuccinic acid (DMSA), diethylenetriaminetetramethylenephosphonic acid (DTTP) and l-(p- .aminobenzyl)-DTPA, 1,6-diamino hexane-N,N,N ⁇ N'-tetraacetic acid, DPDP, and ethylenebis (oxyethylenenitrilo)-tetraacetic acid,
- the paclitaxel, docetaxel, or other taxoid may be conjugated to a water soluble polymer, and preferably the polymer is conjugated to the 2' or the 7- hydroxyl or both of the paclitaxel, docetaxel, or other taxoid.
- Poly-glutamic acid (PG) is one polymer that offers several advantages in the present invention. First, it contains a large number of side chain carboxyl functional groups for drug attachment. Second, PG can be readily degraded 8 by lysosomal enzymes to its nontoxic basic component, 1-glutamic acid, d-glutamic acid and dl-glutamic acid.
- Preferred polymers include, but are not limited to poly(l-glutamic acid), poly(d-glutamic acid), poly(dl-glutamic acid), poly-aspartic acid), poly(d-aspartic acid), poly(dl-aspartic acid), poly ⁇ l-lysine), poly-lysine), poly(dl-lysine), copolymers of the above listed polyamino acids with polyethylene glycol, polycaprolactone, polyglycolic acid and polylactic acid, as well as poly(2-hydroxyethyl 1-glutamine), chitosan, carboxymethyl dextran, hyaluronic acid, human serum albumin and alginic acid, with poly-glutamic acids being particularly preferred.
- the polymers of the present invention preferably have a molecular weight of about 1,000, about 2,000, about 3,000, about 4,000, about 5,000, about 6,000, about 7,000, about 8,000, about 9,000, about 10,000, about 11,000, about 12,000, about 13,000, about 14,000, about 15,000, about 16,000, about 17,000, about 18,000, about 19,000, about 20,000, about 21,000, about 22,000, about 23,000, about 24,000, about 25,000, about 26,000, about 27,000, about 28,000, about 29,000, about 30,000, about 31,000, about 32,000, about 33,000, about 34,000, about 35,000, about 36,000, about 37,000, about 38,000, about 39,000, about 40,000, about 41,000, about 42,000, about 43,000, about 44,000, about 45,000, about 46,000, about 47,000, about 48,000, about 49,000, to about 50,000 kd.
- the polymers of the present invention preferably have a molecular weight of about 51,000, about 52,000, about 53,000, about 54,000, about 55,000, about 56,000, about 57,000, about 58,000, about 59,000, about 60,000, about 61,000, about 62,000, about 63,000, about 64,000, about 65,000, about 66,000, about 67,000, about 68,000, about 69,000, about 70,000, about 71,000, about 72,000, about 73,000, about 74,000, about 75,000, about 76,000, about 77,000, about 78,000, about 79,000, about 80,000, about 81,000, about 82,000, about 83,000, about 84,000, about 85,000, about 86,000, about 87,000, about 88,000, about 89,000, about 90,000, about 91,000, about 92,000, about 93,000, about 94,000, about 95,000, about 96,000, about 97,000, about 98,000, about 99,000, to about 100,000 kd.
- the ranges of molecutar weights for the polymers are preferably of about 91,000, about 92,000, about 93,000, about
- composition of the invention such as PG-TXL may also be conjugated to a second lipophilic or poorly soluble antitumor agent such as camptothecin, epothilone, cisplatin, melphalan, Taxotere, etoposide, teniposide, fiudarabine, verapamil, or cyclosporin, for example, or even to water soluble agents such as 5 fluorouracil (5 FU) or fluorodeoxyuridine (FUDR), doxorubicin or daunomycin.
- a second lipophilic or poorly soluble antitumor agent such as camptothecin, epothilone, cisplatin, melphalan, Taxotere, etoposide, teniposide, fiudarabine, verapamil, or cyclosporin, for example, or even to water soluble agents such as 5 fluorouracil (5 FU) or fluorodeoxyuridine (FUDR), dox
- compositions of the present invention may be dispersed in a pharmaceutically acceptable carrier solution as described below.
- a pharmaceutically acceptable carrier solution would be sterile or aseptic and may include water, buffers, isotonic agents or other ingredients known to those of skill in the art that would cause no allergic or other harmful reaction when administered to an animal or human subject. Therefore, the present invention may also be described as a pharmaceutical composition comprising a chemotherapeutic or anti-cancer drug such as paclitaxel, docetaxel, or other taxoid conjugated to a high molecular weight water soluble polymer or to a chelator.
- a chemotherapeutic or anti-cancer drug such as paclitaxel, docetaxel, or other taxoid conjugated to a high molecular weight water soluble polymer or to a chelator.
- the pharmaceutical composition may include polyethylene glycol, poly- glutamic acids, poly-aspartic acids, poly-lysine, or a chelator, preferably DTPA. It is also understood that a radionuclide may be used as an anti-tumor agent, or drug, and that the present pharmaceutical composition may include a therapeutic amount of a chelated radioactive isotope.
- the present invention may be described as a method of determining the uptake of a chemotherapeutic drug such as paclitaxel, docetaxel, or other taxoid by tumor tissue.
- This method may comprise obtaining a conjugate of the drug and a metal chelator with a chelated metal ion, contacting tumor tissue with the composition and detecting the presence of the chelated metal ion in the tumor tissue.
- the presence of the chelated metal ion in the tumor tissue is indicative of uptake by the tumor tissue.
- the chelated metal ion may be a radionuclide and the detection may 10
- the tumor tissue may also be contained in an animal or a human subject and the composition would then be administered to the subject.
- the present invention may also be described in certain embodiments as a method of treating cancer in a subject.
- This method includes obtaining a composition comprising a chemotherapeutic drug such as paclitaxel, docetaxel, or other taxoid conjugated to a water soluble polymer or chelator and dispersed in a pharmaceutically acceptable solution and administering the solution to the subject in .an .amount effective to treat the tumor.
- a chemotherapeutic drug such as paclitaxel, docetaxel, or other taxoid conjugated to a water soluble polymer or chelator and dispersed in a pharmaceutically acceptable solution
- compositions comprise paclitaxel, docetaxel, or other taxoid conjugated to a water soluble polyamino acids, including but not limited to poly (1-aspartic acid), poly (d-aspartic acid), or poly (dl-aspartic acid), poly (1- lysine acid), poly (d-lysine acid), or poly (dl-lysine acid), and more preferably to poly (1-glutamic acid), poly (d-glutamic acid), or poly (dl-glutamic acid).
- a water soluble polyamino acids including but not limited to poly (1-aspartic acid), poly (d-aspartic acid), or poly (dl-aspartic acid), poly (1- lysine acid), poly (d-lysine acid), or poly (dl-lysine acid), and more preferably to poly (1-glutamic acid), poly (d-glutamic acid), or poly (dl-glutamic acid).
- compositions of the invention are understood to be effective against any type of cancer for which the unconjugated taxoid is shown to be effective and would include, but not be limited to breast cancer, ovarian cancer, malignant melanoma, lung cancer, head and neck cancer.
- the compositions of the invention may also be used against gastric cancer, prostate cancer, colon cancer, leukemia, or Kaposi's Sarcoma.
- the term "treating" cancer is understood as meaning any medical management of a subject having a tumor. The term would encompass any inhibition of tumor growth or metastasis, or any attempt to inhibit, slow or abrogate tumor growth or metastasis.
- the method includes killing a cancer cell by non-apoptotic as well as apoptotic mechanisms of cell death.
- the method of treating a tumor may include some prediction of the paclitaxel or docetaxel uptake in the tumor prior to administering a therapeutic amount of the drug, by methods that include but are not limited to bolus injection or infusion, as well as intraarterial, intravenous, intraperitoneal, or intratumoral administration of the drug.
- This method may include any of the imaging techniques discussed above in which a paclitaxel-chelator-chelated metal is administered to a subject and detected in a tumor. This step provides a cost effective way of determining that a particular tumor would not be expected to respond to DTPA-paclitaxel therapy in those cases 1 1 where the drug does not get into the tumor. It is contemplated that if an imaging technique can be used to predict the response to paclitaxel and to identify patients that are not likely to respond, great expense and crucial time may be saved for the patient. The assumption is that if there is no reasonable amount of chemotherapeutic agent deposited in the tumor, the probability of tumor response to that agent is relatively small.
- the present invention may be described as a method of obtaining a body image of a subject.
- the body image is obtained by administering an effective amount of a radioactive metal ion chelated to a paclitaxel-chelator conjugate to a subject and measuring the scintigraphic signals of the radioactive metal to obtain an image.
- the present invention may also be described in certain broad aspects as a method of decreasing at least one symptom of a systemic autoimmune disease comprising administering to a subject, having a systemic autoimmune disease an effective amount of a composition comprising paclitaxel or docetaxel conjugated to polymer, with poly-amino acids being preferred and poly-glutamic acid being more prefeired.
- a composition comprising paclitaxel or docetaxel conjugated to polymer, with poly-amino acids being preferred and poly-glutamic acid being more prefeired.
- Cremophor formulation US Patent 5,583,153, incorporated herein by reference.
- compositions of the present invention are expected to be as effective as paclitaxel against rheumatoid arthritis.
- Paclitaxel is an antiangiogenic agent.
- Rheumatoid arthritis creates a collection of newly formed vessels which erode the adjacent joints.
- the taxoid or taxane compositions of the present invention may be used in combination with other drugs, such as an angiogenesis inhibitor (AGM-1470) (Oliver et ⁇ l, 1994), or other anti-cancer drugs, such as methotrexate. 12
- water soluble paclitaxels and docetaxels of the present invention will find a variety of applications beyond direct parenteral administration (WO 9625176, incorporated herein by reference).
- water soluble paclitaxel will be useful as a coating for implanted medical devices, such as tubings, shunts, catheters, artificial implants, pins, electrical implants such as pacemakers, and especially for arterial or venous stents, including balloon-expandable stents.
- water soluble paclitaxel may be bound to an implantable medical device, or alternatively, the water soluble paclitaxel may be passively adsorbed to the surface of the implantable device.
- stents may be coated with polymer-drug conjugates by dipping the stent in polymer-drug solution or spraying the stent with such a solution.
- Suitable materials for the implantable device should be biocompatible and nontoxic and may be chosen from the metals such as nickel-titanium alloys, steel, or biocompatible polymers, hydrogels, polyurethanes, polyethylenes, ethylenevinyl acetate copolymers, etc.
- the water soluble paclitaxel is coated onto a stent for insertion into an artery or vein following balloon angioplasty.
- the invention may be described therefore, in certain broad aspects as a method of inhibiting arterial restenosis or arterial occlusion following vascular trauma comprising administering to a subject in need thereof, a composition comprising paclitaxel or docetaxel conjugated to poly-glutamic acid or other water soluble poly-amino acids.
- the subject may be a coronary bypass, vascular surgery, organ transplant or coronary or any other arterial angioplasty patient, for example, and the composition may be administered directly, intravenously, or even coated on a stent to be implanted at the sight of vascular trauma.
- An embodiment of the invention is, therefore, .an implantable medical device, wherein the device is coated with a composition comprising paclitaxel or docetaxel conjugated to poly-glutamic acids or water soluble polyamino acids in an amount effective to inhibit smooth muscle cell proliferation.
- a preferred device is a stent 13 coated with the compositions of the present invention as described herein, and in certain preferred embodiments, the stent is adapted to be used during or after balloon angioplasty and the coating is effective to inhibit restenosis.
- the invention may be described as a composition comprising poly-glutamic acids conjugated to the 2"or 7 hydroxyl or both of paclitaxel, docetaxel, or other taxoids, or even a composition comprising water soluble polyamino acids conjugated to the 2' or 7 hydroxyl or both of paclitaxel, docetaxel, or other taxoids.
- a poly-glutamic acid or “poly-glutamic acids” include poly (1-glutamic acid), poly (d-glutamic acid) and poly (dl-glutamic acid), the terms “a poly-aspartic acid” or “poly-aspartic acids” include poly (1-aspartic acid), poly (d-aspartic acid), poly (dl-aspartic acid), the terms “a poly-lysine” or “poly- lysine” include poly (1-lysine), poly (d-lysine), poly (dl-lysine), .and the terms "a water soluble polyamino acid”, “water soluble polyamino acids”, or “water soluble polymer of amino acids” include, but are not limited to, poly-glutamic acid, poly-aspartic acid, poly-lysine, and amino acid chains comprising mixtures of glutamic acid, aspartic acid, and/or lysine.
- a water soluble polyamino acid examples include amino acid chains comprising combinations of glutamic acid and/or aspartic acid and/or lysine, of either d and/or 1 isomer conformation.
- such a “water soluble polyamino acid” contains one or more glutamic acid, aspartic acid, and/or lysine residues.
- Such “water soluble polyamino acids” may also comprise any natural, modified, or unusual amino acid described herein, as long as the majority of residues, i.e.
- a water soluble polymer of amino acids that contains more than one different type of .amino acid residue is sometimes referred to herein as a "co-polymer".
- various substitutions of naturally occurring, unussual, or chemically modified amino acids may be made in the amino acid composition of the "water soluble polyamino acids", and particularly in “poly-glutamic acids", to produce a taxoid-polyamino acid conjugate of the present invention and still obtain molecules having like or otherwise desirable characteristics of solubility and/or therapeutic efficacy.
- a polyamino acid such as poly-glutamic acid, poly-aspartic acid, poly-lysine, or water soluble amino acids chain or polymer comprising a mixture of glutamic acid, aspartic acid, and/or lysine, may, at the lower end of the amino acid substitution range, have about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, or about 25 or more glutamic acid, aspartic acid, or lysine, residues, respectively, substituted by any of the naturally occurring, modified, or unusual amino acids described herein.
- a polyamino acid such as poly-glutamic acid, poly- aspartic acid, poly-lysine, or a poly-amino acid chain comprising a mixture of some or all of these three amino acids may, at the lower end, have about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, to about 25% or more glutamic acid, aspartic acid, or lysine residues, respectively, substituted by .any of the naturally occurring, modified, or unusual amino acids described herein.
- a polyamino acid such as poly-glutamic acid, poly-aspartic acid, or poly-lysine may, at the high end of the amino acid substitution range, have about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, to about 50% or so of the glutamic acid, aspartic acid, or lysine residues, respectively, substituted by .any of the naturally occurring, modified, or unusual amino acids described herein, as 15
- residues long as the majority of residues comprise glutamic acid and/or aspartic acid and/or lysine.
- residues with a hydrophilicity index of +1 or more are preferred.
- the amount of anti-tumor drug conjugated per water soluble polymer can vary.
- such a "composition may comprise from about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, or about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21% about 22%, about 23%, about 24%, to about 25% (w/w) antitumor drug relative to the mass of the conjugate.
- such a composition may comprise from about 26%, about 27%, about 28%, about 29%, about 30%, about 31% about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, to about 40% or more (w/w) antitumor drug relative to the mass of the conjugate.
- Preferred anti-tumor drugs include paclitaxel, docetaxel, or other taxoids, .and preferred water soluble polymers include water soluble amino acid polymers.
- the number of molecules of antitumor drug conjugated per molecule of water soluble polymer can vary. At the lower end, such a composition may comprise from about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, to about 20 or more molecules of antitumor drug per molecule of water soluble polymer.
- such a composition may comprise from about 21, about 22, about 23, about 24, about 25, about 26, about 27, about 28, about 29, about 30, about 31, about 32, about 33, about 34, about 35, about 36, about 37, about 38, about 39, about 40, about 41, about 42, about 43, about 44, about 45, about 46, about 47, about 48, about 49, about 50, about 51, about 52, about 53, about 54, about 55, about 56, about 57, about 58, about 59, about 60 about 61, about 62, about 63, about 64, about 65, about 66, about 67, about 68, about 69, about 70, about 71, about 72, about 73, about 74, to about 75 or more molecules or more of antitumor drug per molecule of water soluble polymer.
- Preferred anti-tumor drugs include paclitaxel, docetaxel, or other taxoids, .and preferred water soluble polymers include water soluble amino acid polymers.
- the preferred number of anti-tumor drug molecules conjugated per molecule of water soluble polymer is about 7 molecules of antitumor drug per molecule of water soluble polymer.
- Biological functional equivalents Water soluble amino acid polymers with various substitutions of residues conjugated to paclitaxel, docetaxel, or other taxoids are referred to as "biological functional equivalents". These "biologically functional equivalents" are part of the ' definition of "water soluble polyamino acids” that are conjugated to taxoids, and may be identified by the assays described herein as well as any applicable assay that is known to those of skill in the art to measure improved aqueous solubility relative to the unconjugated taxoid or taxoids used to produce the particular water soluble amino acid polymer-taxoid composition.
- biological functional equivalents of water soluble amino acid-taxoid polymers may be further identified by improved anti-tumor cell activity, relative to the anti-tumor cell activity of the unconjugated water soluble amino acid polymer used to produce the particular water soluble amino acid polymer-taxoid composition by the assays described herein as well as any applicable assay that is known to those of skill in the .art.
- biologically functional equivalents as used herein to describe this aspect of the invention is further described in the detailed description of the invention.
- FIG. 1 A Chemical structure of paclitaxel, PEG-paclitaxel and DTPA-paclitaxel. 17
- FIG. IB Chemical structure and reaction scheme for production of PG-TXL.
- FIG. 2 Effect of paclitaxel, PEG-paclitaxel and DTPA-paclitaxel on proliferation of B 16 melanoma cells.
- FIG. 3 Antitumor effect of DTPA-paclitaxel on MCa-4 mammary tumors.
- FIG. 4 Median time (days) to reach tumor diameter of 12 mm after treatment with paclitaxel, DTPA-paclitaxel and PEG-paclitaxel.
- FIG. 5 Gamma-scintigraphs of mice bearing MCa-4 tumors following intravenous injection of m In-DTPA-paclitaxel and ⁇ n In-DTPA. .Arrow indicates the tumor.
- FIG. 6 Hydrolytic degradation of PG-TXL as determined in PBS as a function of time at different pH levels. -0- represents percent paclitaxel released, -O- represents metabolite- 1 produced.
- FIG. 7B Anti-tumor effect of PG-TXL against 13762F tumor in female rats.
- -•- represents PG-TXL (20 mg equivalent 18
- FIG. 7C The antitumor effect of PG-TXL on mice bearing MCa-4 mammary carcinoma tumors.
- -D- represents the response to a single i.v. dose of saline
- - ⁇ - represents the response to a single i.v. dose of PG (0.6 g/kg)
- - ⁇ - represents response to PG-TXL (40 mg/kg)
- -0- represents response to PG-TXL (60 mg equiv. paclitaxel/kg)
- -O- represents response to PG-TXL (120 mg/kg).
- FIG. 7D The antitumor effect of PG-TXL against soft-tissue sarcoma tumor (FSa-II) in mice.
- -D- represents the response to a single i.v. dose of saline
- -0- represents the response to a single i.v. dose of PG (0.8 g/kg)
- -O- represents response to paclitaxel (80 mg/'kg)
- - ⁇ - represents response to PG-TXL (160 mg equiv. paclitaxel/T g).
- FIG. 7E The antitumor effect of PG-TXL against syngeneic hepatocarcinoma tumor (HCa-I) in mice.
- -D- represents the response to a single i.v. dose of saline
- - ⁇ - represents the response to a single i.v. dose of PG (0.8 g/kg)
- -O- represents response to PG-TXL (80 mg/kg)
- - ⁇ - represents response to PG-TXL (160 mg equiv. paclitaxel/kg).
- FIG. 8 Release profile of paclitaxel from PEG-paclitaxel in phosphate buffer (pH 7.4). Release profiles of paclitaxel (-X-); from PEG-paclitaxel (-0-) at pH 7.4 is shown.
- FIG. 9. Antitumor effect of PEG-paclitaxel on MCa-4 mammary tumors.
- - ⁇ - represents the response a single i.v. injection with a saline solution of PEG (60 mg/ml)
- - ⁇ - represents the response to the Cremophor/alcohol vehicle
- -O- represents a single dose of 40 mg/kg body weight of paclitaxel
- -•- represents PEG- paclitaxel at 40 mg equiv. paclitaxel/kg body weight. 19
- FIG. 10 Tubulin polymerization assays performed at 32°C in the presence of 1.0 mM GTP and 1.0 mg/ml of tubulin.
- - ⁇ - represents paclitaxel (1.0 ⁇ M)
- - ⁇ - represents PG-TXL (10 ⁇ M equivalent paclitaxel) incubated in PBS (pH 7.4) at 37°C for 3 days
- -O- represents freshly dissolved PG-TXL.
- FIG. 11 Plasma clearance of radioactivity following -an i.v. injection of PG- [ 3 H]paclitaxel and [ 3 H]paclitaxel in C3Hf/Kam mice.
- - ⁇ - represents PG-TXL radioactivity after injection of 6 ⁇ Ci of radiolabeled PG-[ 3 H]paclitaxel (20 mg equivalent paclitaxel,kg)
- -x- represents paclitaxel radioactivity after injection of 6 ⁇ Ci of radiolabeled [ HJpaclitaxel (20 mg equivalent paclitaxel/kg)
- -O- represents "Paclitaxel" radioactivity released from injected PG-[ HJpaclitaxel.
- FIG. 12 A Time-dependent OCA-1 tumor content of radioactivity following injection of either PG-[ HJpaclitaxel and [ HJpaclitaxel into mice.
- Open bars represents PG- TXL radioactivity after injection of 6 ⁇ Ci of radiolabeled PG-[ HJpaclitaxel (20 mg equivalent paclitaxel/ / kg), filled
- b.ars represents paclitaxel radioactivity after injection of 6 ⁇ Ci of radiolabeled [ 3 HJpaclitaxel (20 mg equivalent paclitaxel kg).
- FIG. 12B Conversion of PG-[ 3 HJpaclitaxel to [ 3 HJpaclitaxel within OCA-1 tumor. Total radioactivity measured .after injection of 6 ⁇ Ci of radiolabeled PG- [ HJpaclitaxel is shown in open bars, "Paclitaxel" derived radioactivity released from injected PG-[ HJpaclitaxel is shown in solid bars.
- FIG. 13 Kinetics of apoptosis in OCA-1 tumors after a single i.v. dose of 160 mg equiv. paclitaxel/kg of PG-TXL (MTD) and 80 mg/kg paclitaxel (MTD).
- - ⁇ - represents the response to a single i.v. dose of PG-TXL (160 mg equiv. paclitaxel/kg MTD)
- -O- represents response to paclitaxel (80 mg paclitaxel/kg MTD).
- FIG. 14 Survival of nude mice with human ovarian cancer cells (SKON3ipl) treated with PG-TXL. Five days after tumor injection, the mice were injected i.v. with the 20
- PG-paclitaxel PG-TXL
- PG control PG-paclitaxel
- Injections of PG-TXL were administered every seven days (T) in the 120 mg/kg group, but not the 160 mg/kg group.
- - ⁇ - represents untreated mice.
- -A- represents the response to multiple i.v. doses of PG.
- -T- represents the response to an i.v. dose of PG-TXL (120 mg equiv. paclitaxel/kg)
- - ⁇ - represents the response to an i.v. dose of PG-TXL (160 mg equiv. paclitaxel/kg).
- FIG. 15 Chemical structure and reaction scheme for production of glutamic acid containing polyamino acids.
- the present invention arises from the discovery of novel, water soluble formulations of paclitaxel and docetaxel, and the surprising efficacy of these formulations against tumor cells in vivo.
- Poly (1-glutamic acid) conjugated paclitaxel (PG-TXL) administered to mice bearing ovarian carcinoma (OCA-I) caused significant tumor growth delay as compared to the same dose of paclitaxel without PG.
- Mice treated with paclitaxel alone or with a combination of free paclitaxel and PG showed delayed tumor growth initially, but tumors regrew to levels comparable to an untreated control group after ten days.
- MTD maximum tolerated dose
- PG- TXL is a novel species of taxane that is pharmacologically distinct from previous paclitaxel or Taxol preparations.
- the distribution of PG-TXL within plasma is distinct from free paclitaxel. While paclitaxel remains in the plasma of mice for an extremely short time, PG-TXL appears to remain for a much longer period. This is contemplated to offer a distinct advantage in that prolonged exposure of tumors to the drug may result in an enhanced response.
- the rate of conversion of PG-TXL to paclitaxel is slow, with less than 1% of the radioactivity from radiolabeled PG-TXL being recovered as radioactive paclitaxel within 48 h after injection of the paclitaxel-polymer complex.
- the novel drug, PG-TXL may produce death within tumor cells in a manner which is not simply due to the gradual release of paclitaxel itself.
- Another aspect of the present invention is the inclusion of molecules in the polymeric composition that are effective to target the therapeutic composition to a disease or tumor site or to a particular organ or tissue.
- Many of such targeting molecules are known in the .art and may be conjugated to the water soluble anti-tumor compositions of the present invention.
- Examples of such molecules or agents would include, but not be limited to antibodies such as anti-tumor antibodies; anti-cell receptor antibodies; tissue specific antibodies; hormonal agents such as octreotide, estradiol and tamoxifen; growth factors; cell surface receptor ligands; enzymes; hypoxic agents such as misonidazole and erythronitroimid.azole; and .antiangiogenic agents.
- composition of the present invention is DTPA-paclitaxel, also shown herein to be as effective as paclitaxel in an in vitro .antitumor potency assay using a B 16 melanoma cell line.
- DTPA-paclitaxel did not show any significant difference in antitumor effect as compared to paclitaxel against an MCa-4 mammary tumor at a dose of 40 mg/kg body weight in a single injection.
- ' Indium labeled DTPA-paclitaxel was shown to accumulate in the MCa-4 tumor as demonstrated by gamma-scintigraphy, demonstrating that the chelator conjugated anti-tumor drugs of the present invention are useful and effective for tumor imaging.
- novel compounds and methods of the present invention provide significant advances over prior methods and compositions, as the water-soluble paclitaxels are projected to improve the efficacy of paclitaxel-based anti-cancer therapy, by providing water soluble and controlled release paclitaxel derived compositions that also have different antitumor properties than unmodified paclitaxel.
- Such compositions eliminate the need for solvents that are associated with side effects seen with prior paclitaxel compositions.
- radiolabeled paclitaxel which is shown to retain anti-rumor activity, will also be useful in the imaging of tumors.
- the present invention allows one to determine whether a paclitaxel will be taken up by a particular tumor by scintigraphy, single photon emission computer tomography (SPECT) or positron emission tomography (PET). This determination may then be used to predict the efficacy of an anti-cancer treatment. This information may be helpful in guiding the practitioner in the selection of patients to undergo chelator-paclitaxel therapy.
- SPECT single photon emission computer tomography
- PET positron emission tomography
- the paclitaxel may be rendered water-soluble in many ways: i.e. by conjugating paclitaxel to water-soluble polymers which serve as drug carriers, and by derivatizing the .antitumor drug with water soluble chelating agents.
- the latter approach also provides an opportunity for labeling with radionuclides (e.g., In, Y, Ho, Ga, m Tc) for nuclear imaging and/or for radiotherapy studies.
- radionuclides e.g., In, Y, Ho, Ga, m Tc
- PG-TXL glutamic acid-paclitaxel conjugate
- DTPA-paclitaxel diethylenetriaminepentaacetic acid- paclitaxel
- DTPA-paclitaxel or other paclitaxel-chelating agent conjugates such as EDTA-paclitaxel, DTTP-paclitaxel, or DOTA-paclitaxel, for example, may be prepared in the form of water-soluble salts (sodium salt, potassium salt, tetrabutylammonium salt, calcium salt, ferric salt, etc.). These salts will be useful as therapeutic agents for tumor treatment. Secondly, DTPA-paclitaxel or other paclitaxel-chelating agents will be useful as diagnostic agents which, when labeled with radionuclides such as "in or 99m Tc, may be used as radiotracers to detect certain tumors in combination with nuclear imaging techniques.
- radionuclides such as "in or 99m Tc
- Taxane derivatives may be adapted for use in the compositions and methods of the present invention and that all such compositions and methods would be encompassed by the present invention.
- amino acids may be substituted for other amino acids in a polyamino acid structure, including water soluble amino acid polymers such as poly-glutamic acid, poly-aspartic acid, or poly- lysine, without appreciable loss of interactive binding capacity with structures such as, for example, a chemotherapeutic and/or antiangiogenic drug, such as paclitaxel or docetaxel, or such like.
- a chemotherapeutic and/or antiangiogenic drug such as paclitaxel or docetaxel, or such like.
- amino acid substitutions in a water soluble polyamino acid conjugated to a chemotherapeutic and/or antiangiogenic drug such as paclitaxel or docetaxel, or such like, as exemplified by but not limited to PG-TXL, may be made and still maintain part or all of the novel pharmacological properties 25 disclosed herein. Since it is the interactive capacity and nature of a protein that defines that protein's biological functional activity, certain amino acid sequence substitutions can be made in a polyamino acid sequence and nevertheless obtain a polyamino acid with like (agonistic) properties. It is thus contemplated by the inventors that various changes may be made in the sequence of the water soluble polyamino acids of a drug conjugate, such as, but not limited to * TG-TXL, without appreciable loss of their biological utility or activity.
- Biologically functional equivalent of a water soluble polyamino acid is the concept that there is a limit to the number of changes that may be made within a portion of the molecule and still result in a molecule with an acceptable level of equivalent biological activity.
- Biologically functional equivalent of a water soluble polyamino acids are thus defined herein as those water soluble polyamino acids in which certain, not most or all, of the amino acids may be substituted by non-water soluble amino acids, whether natural, unusual, or chemically modified.
- water soluble polyamino acids In particular, where shorter length water soluble polyamino acids are concerned, it is contemplated that fewer amino acids should be made within the given peptide. Longer domains may have an intermediate number of changes. The longest water soluble polyamino acid chains, as described herein, will have the most toler.ance for a larger number of changes. Of course, a plurality of distinct water soluble polyamino acids, such as but not limited to poly glutamic acid, poly aspartic acid, or poly-lysine, with different substitutions may easily be made and used in accordance with the invention.
- amino acid substitutions are generally based on the relative similarity of the amino acid side-chain substituents, for example, their hydrophobicity, hydrophilicity, charge, size, and the like.
- An analysis of the size, shape and type * bf the amino acid side-chain substituents reveals that arginine, lysine and histidine are all positively charged residues; that alanine, glycine and serine are all a similar size; and that phenylalanine, tryptophan and tyrosine all have a generally similar shape.
- arginine, lysine and histidine; alanine, glycine and serine; and phenylalanine, tryptophan and tyrosine; are defined herein as biologically functional equivalents.
- hydropathic index of amino acids may be considered.
- Each amino acid has been assigned a hydropathic index on the basis of their hydrophobicity and charge characteristics, these are: isoleucine (+4.5) valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine/cystine (+2.5) methionine (+1.9); alanine (+1.8); glycine (-0.4); threonine (-0J); serine (-0.8) tryptophan (-0.9); tyrosine (-1.3); proline (-1.6); histidine (-3.2); glutamate (-3.5) glutamine (-3.5); aspartate (-3.5); asparagine (-3.5); lysine (-3.9); and arginine (-4.5).
- hydrophilicity values have been assigned to amino acid residues: arginine (+3.0); lysine (+3.0); aspartate (+3.0 ⁇ 1); glutamate (+3.0 ⁇ 1); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); threonine (-0.4); proline (-0.5 ⁇ 1); alanine (-0.5); histidine (-0.5); cysteine (-1.0); methionine (-'1.3); valine (-1.5); leucine (-1.8); isoleucine (-1.8); tyrosine (-2.3); phenylalanine (-2.5); tryptophan (-3.4).
- hydrophilicity In making changes based upon similar hydrophilicity values, the substitution of amino acids whose hydrophilicity values are within ⁇ 2 is preferred, those which are within ⁇ 1 are particularly preferred, and those within ⁇ 0.5 are even more particul.arly preferred.
- .arginine, lysine, aspartic acid, and glutamic acid are defined herein as biologically functional equivalents, particularly in water soluble amino acid polymers.
- water soluble polyamino acid-chemotherapeutic and/or antiangiogenic drug compounds described herein such as paclitaxel or docetaxel conjugated to a water soluble amino acid, or such like, as exemplified by, but not limited to PG-TXL compounds described herein
- the inventors also contemplate that other sterically similar compounds may be formulated to mimic the key portions of the water soluble polyamino acid structure.
- Such compounds which may be termed peptidomimetics, may be used in the same manner as the peptides of the invention and hence are also functional equivalents.
- ⁇ -turn structure within a polypeptide can be predicted by computer-based algorithms, as discussed herein. Once the component amino acids of the turn are determined, mimetics can be constructed to achieve a similar spatial orientation of the essential elements of the amino acid side chains.
- modified or unusual amino acids are also contemplated for use in the present invention.
- a table of exemplary, but not limiting, modified or unusual amino acids is provided herein below.
- mice Toxicity studies, pharmacokinetics and tissue distribution of DTPA-paclitaxel have shown that in mice the LD 50 (50% lethal dose) of DPTA-paclitaxel observed with a single dose intravenous (iv) injection is about 110 mg/kg body weight. Direct comparison with paclitaxel is difficult to make because of the dose-volume constraints imposed by limited solubility of paclitaxel and vehicle toxicity associated with iv administration. However, in light of the present disclosure, one skilled in the art of chemotherapy would determine the effective .and maximum tolerated doses (MTD) in a clinical study for use in human subjects.
- MTD maximum tolerated doses
- a stent coated with the polymer- paclitaxel conjugates may be used to prevent restenosis, the closure of .arteries following balloon angioplasty.
- Recent results in clinical trials using balloon- expandable stents in coronary angioplasty have shown a significant benefit in patency and the reduction of restenosis compared to standard balloon angioplasty (Serruys et ⁇ , 1994).
- neointima formation is associated with increased cell proliferation.
- SMC smooth muscle cell
- anti-cancer drugs may be useful to prevent neointimal SMC accumulation.
- Stents coated with polymer-linked anti-proliferative agents that are capable of releasing these agents over a prolonged period of time with sufficient concentration will thus prevent ingrowth of hyperplastic intima and media into the lumen thereby reducing restenosis.
- paclitaxel has been shown to suppress collagen induced arthritis in a mouse model (Oliver et al. 1994), the formulations of the present invention are also contemplated to be useful in the treatment of autoimmune and/or inflammatory diseases such as rheumatoid arthritis.
- Paclitaxel binding to tubulin shifts the equilibrium to stable microtubule polymers and makes this drug a strong inhibitor of eukaryotic cell replication by blocking cells in the late G2 mitotic stage.
- Several mechanisms may be involved in arthritis suppression by paclitaxel.
- paclitaxel's phase specific cytotoxic effects may affect rapidly proliferating infl-ammatory cells, .and furthermore paclitaxel inhibits cell mitosis, migration, chemotaxis, intracellular transport and neutrophil H 2 0 2 production.
- paclitaxel may have antiangiogenic activity by blocking coordinated endothelial cell migration (Oliver et al 1994). Therefore, the water soluble polyamino acids conjugated paclitaxel of the present invention are contemplated to be useful in the treatment of rheumatoid arthritis.
- the polymer conjugated formulation disclosed herein would also offer the advantages of controlled release of the drug and greater solubility. It is also an aspect of the treatment of arthritis that the formulations may be injected or implanted directly into the affected joint areas.
- the pharmaceutical preparations of paclitaxel or docetaxel suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the preparation of sterile injectable solutions or dispersions.
- the form must be sterile and must be fluid for injection. It must be stable under the conditions 31 of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi.
- the carrier may be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils.
- microorganisms can be brought about by various antibacterial and antifungal ag ⁇ nts, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like.
- isotonic agents for example, sugars or sodium chloride.
- Sterile injectable solutions are prepared by incorporating the active compounds in the required .amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization.
- dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
- the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile- filtered solution thereof.
- pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents and isotonic agents and the like.
- the use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions. 32
- phrases “pharmaceutically acceptable” also refers to molecular entities and compositions that do not produce an allergic or similar untoward reaction when administered to an animal or a human.
- aqueous solutions For parenteral administration in an aqueous solution, for example, the solution should be suitably buffered if necessary and the liquid diluent first" rendered isotonic with sufficient saline or glucose.
- aqueous solutions are especially suitable for intravenous and intraperitoneal administration.
- sterile aqueous media which can be employed will be known to those of skill in the art in light of the present disclosure.
- Example 1 Poly-glutamic Acid-Paclitaxel (PG-TXL)
- PG-TXL Poly-glutamic Acid-Paclitaxel
- the present example concerns a first study involving the conjugation of paclitaxel to a water-soluble polymer, poly (1-glutamic acid) (PG) and the efficacy of the preparation against a variety of tumors in mice and rats.
- PG poly (1-glutamic acid)
- the potential of water- soluble polymers used as drug carriers is well established (Kopecek, 1990; Maeda and Matsumura, 1989).
- PG-TXL Poly-Gutamic Acid-Paclitaxel
- FIG. IB Poly( 1-glutamic acid) (PG) sodium salt was obtained from Sigma (St. Louis, MO). The polymer by viscosity had a molecular weight of 36,200, and number-average molecular weight (M n ) of 24,000 as determined by low-angle laser light scattering (LALLS). Lot-specific polydispersity Q ⁇ My) was 1.15 where M w is weight-average molecular weight.
- PG sodium salt (MW 34 K, Sigma, 0.35 g) was first convened to PG in its proton form. The pH of the aqueous PG sodium salt solution was adjusted to 2.0 using 0.2 M HC1. The precipitate was collected, dialyzed against distilled water, and lyophilized to yield 0.29 g PG.
- PG 75 mg, repeating unit FW 170, 0.44 mmol
- DMF dry N,N-dimethylformamide
- DCC dicyclohexylcarbodiimide
- DMAP trace amount of dimethylaminopyridine
- Paclitaxel was supplied by Hande Tech (Houston, TX), and the purity was 99% and higher as confirmed by HPLC assay.
- the sodium salt of PG-TXL conjugate was obtained by dissolving the product in 1.0 M NaHC0 3 .
- the aqueous solution of PG-TXL was dialyzed against distilled water (MWCO 10,000) to remove low molecular weight contaminants and excess NaHC03 salt. Lyophilization of the dialysate yielded 98 mg of product as a white powder.
- the paclitaxel content in this polymeric conjugate as determined by UV was 20-22% (w/w). Yield: 98% (conversion to polymer bound" paclitaxel, UV). Solubility in water > 20 mg paclitaxel/ml.
- a similar method can be used to synthesize PG-TXL with higher paclitaxel content (up to 35%) by simply increasing the ratio of paclitaxel to PG used.
- Ultraviolet spectra were obtained on a Beckman DU-70 spectrophotometer, using the same concentration of PG aqueous solution as reference.
- PG-TXL showed characteristic paclitaxel absorption with ⁇ max shifts from 228 to 230 urn.
- concentration of paclitaxel in PG-TXL conjugate was estimated based on standard curve generated with known concentrations of paclitaxel in methanol at absorption of 228 nm, assuming that the polymer conjugate in water at 230 nm and the free drug in methanol at 228 nm have the same molar extinction and both follow Lambert Beer's law.
- ⁇ -NMR spectra were recorded with GE model GN 500 (500 MHz) spectrometer in D 2 0. Both the PG moieties .and the paclitaxel moieties were discernible. The couplings of polymer conjugated paclitaxel are too poorly resolved to be measured with sufficient accuracy.
- Resonances at 7J5 to 7.36 ppm are attributable to aromatic components of paclitaxel resonances at 6.38 ppm (C 10 -H), 5.97 ppm (C, 3 -H), 5.63 ppm (C 2 '-H, d), 5.55-5.36 ppm (C 3 *-H and C 2 -H, m), 5.10 ppm (C 5 -H), 4.39 ppm (C 7 -H), 4.10 (C 20 -H), 1.97 ppm (OCOCH 3 ), and 1.18-1.20 ppm (C CH 3 ) are tentatively assigned to aliphatic components of paclitaxel. Other resonances were obscured by the resonances of PG.
- PG- TXL Gel Permeation Chromatography Studies of Poly-Glutamic Acid-Paclitaxel
- GPC gel permeation chromatography
- the GPC system consisted of two LDC model III pumps coupled with LDC gradient master, a PL gel GPC column, and a Waters 990 photodiode array detector.
- the elutant (DMF) was run at 1.0 ml/min with ultraviolet (UV) detection set at 270 nm.
- PG-TXL sodium salt a TSK-gel column suitable for analysis of water-soluble polymer was used, and the system was eluted with 0.2 mM PBS (pH 6.8) at 1.0 ml/min. Conjugation of paclitaxel to PG resulted in an increase in the molecular weight of PG-TXL, as indicated by the shift of retention time from 6.4 min for PG to 5.0 min for PG-TXL conjugate.
- the crude product contained small molecular weight contaminants (retention time 8.0 to 10.0 min, and 11.3 min), which can be effectively removed by convening PG-TXL to its sodium salt, followed by dialysis.
- mice All animal work was carried out at the animal facility at M.D. Anderson Cancer Center in accordance with institutional guidelines. C3H/Kam mice were bred and maintained in a pathogen-free facility in the Department of Experimental Radiation Oncology.
- the tumor growth delay induced by PG-TXL was measured in mammary ovarian carcinoma (OCA-I) implanted in C3Hf/Kam mice. All tumors were syngeneic to this strain. Solitary tumors were produced in the muscle of the right thigh of female C3H/Kam mice (25-30g) by injecting 5 x 10 5 murine ovarian carcinoma cells (OCA-I), mammary carcinoma (MCa-4), hepatocarcinoma (HCa-I) or fibrous sarcoma (FSa-II).
- OCA-I murine ovarian carcinoma cells
- MCa-4 mammary carcinoma
- HCa-I hepatocarcinoma
- FSa-II fibrous sarcoma
- Female Fischer 344 rats 125-150 g were injected with 1.0 x 10 5 viable 13762F tumor cells in 0.1 ml PBS. Treatments were initiated when the tumors in mice had grown to 500 mm 3 (10 mm
- PG-TXL was disolved in saline (10 mg equivalent paclitaxel ml), .and paclitaxel was dissolved in Cremophor EL® vehicle (6 mg/ml). Data are presented as mean ⁇ standard deviation of tumor volumes. In control studies, saline (0.6 ml), Cremophor vehicle [50/50 Cremophor/ethanol diluted with saline (1:4)J, PG solution in saline, and paclitaxel plus PG were used.
- the maximum tolerated dose (MTD) of PG-TXL and paclitaxel in normal female C3Hf/Kam mice was estimated to be 160 mg/kg and 80 mg/kg respectively.
- a single dose of PG-TXL in saline or paclitaxel in Cremophor EL vehicle was given in doses varying from 40 to 160 mg equiv. 37
- Table 2 summarizes acute toxicity of PG paclitaxel in rats in comparison with paclitaxel/Cremophor.
- Table 3 summarizes the data concerning the effect of PG-TXL against MCa-4, FSa-II and HCa-I tumors in mice. The data are also summarized in FIG. 7A-FIG. 7E.
- a PG-TXL solution was prepared by dissolving the conjugate in saline (8 mg equiv. paclitaxel/ml). The injected volume at 60 mg/kg w.as 0.975 ml per rat.
- Paclitaxel Cremophor solution was prepared by dissolving paclitaxel in a 1 : 1 mixture of ethyl alcohol and Cremophor (30 mg/ml). This stock solution was further diluted with saline (1:4) before injection. The final concentration of paclitaxel in the solution was 6 mg/ml.
- the injected volume at 60 mg/kg was
- c PG solution was prepared by dissolving the polymer in saline (22 mg/ml). The injected dose was 0.3 g/kg (1.8 ml per rat), which was equivalent to paclitaxel dose of 60 mg/kg.
- d Cremophor vehicle was prepared by diluting a mixture of ethyl alcohol and
- Cremophor (1:1) with saline (1 :4) 38
- Paclitaxel (80 mg/kg) 6.410.5 (5) -0.9 0.138 PG+Paclitaxel 6J+0.4 (5) -0.6 0.294
- a Mice bearing 500 mm 3 tumors in the right leg were treated with various doses of PG-TXL (40-160 mg equiv. paclitaxel/kg) in saline or paclitaxel in Cremophor vehicle i.v. in a single injection.
- Control animals were treated with saline (0.6 ml), Cremophor vehicle (0.5 ml), PG solution in saline, or PG g/kg) plus paclitaxel (80 mg/kg).
- b Tumor growth was determined by daily measurement of three orthogonal diameters with calipers and the volume was calculated as (A x B x C)/2.
- mice Shown in brackets are the number of mice used in each group.
- the time in days to grow from 500 mm 3 to 2000 mm 3 are presented meanistandard deviation, c Absolute growth delay (AGD) defined as the time in days for tumors treated with various drugs to grow from 500 to 2000 mm minus the time in days for tumors treated with saline control to grow from 500 to 2000 mm 3 .
- ATD Absolute growth delay
- the time in days to grow from 500 to 2000 mm were compared for treatment groups and saline group using Student's t-Test. P-values are two-sided and were taken to be significant when less than to equal 0.05.
- PG-TXL is most effective against MCa-4 and OCA-1 tumors.
- PG-TXL is more effective than paclitaxel on equivalent mg paclitaxel basis in the case of MCa-4, HCa-I, and on OCA-1 tumors, and is remarkably potent at its maximum tolerated dose (MTD).
- MTD maximum tolerated dose
- a single dose of PG- TXL in saline or paclitaxel in a Cremophor EL® vehicle was given in doses varying from 20 to 60 mg equivalent paclitaxel/kg body weight.
- saline, the Cremophor EL® vehicle [50/50 Cremophor/ethanol diluted with saline (1:4)]
- PG solution in saline and paclitaxel plus PG were used.
- complete tumor eradication at the MTD of PG-TXL 60 mg equivalent paclitaxel/kg
- PG-TXL given at a lower dose of 40 mg equivalent paclitaxel/kg also resulted in complete tumor regression (FIG. 7B).
- paclitaxel in Cremophor EL® was less tlran 20 mg kg.
- Paclitaxel at this dose caused a tumor growth delay (Tumor growth delay is defined as the time in days for tumors treated with the test drugs to grow from 2,000 mm 3 to 10,000 mm 3 minus the time in days for tumors treated with saline control to grow from 2,000 mm 3 to 10,000 mm 3 .) of only 5 days, whereas the same equivalent paclitaxel dose of PG-TXL resulted in a tumor growth delay of 23 days (FIG. 7B).
- mice were injected with 2 x 10 MDA-435-Lung2 cells (a variant of the MDA-MB-435 human breast cancer cell line) into the mammary fatpad. When the tumors reached 5 mm mean diameter, (27 days after tumor injection), mice were treated with an i.v. injection of PG-TXL or the various controls (see Table 4). Tumor measurements were taken weekly. Tumors that reached 1.5 cm were removed surgically. All mice were killed at 120 days, and remaining tumors removed and weighed. Mice were examined for metastases, and lungs processed for histology, with single sections of the organs scored for the presence of micrometastases.
- Cremophor 9/9 1.26 + 0.67 - 4/8 (50%)
- nude mice were injected with 2 x 10°; MDA-435-Lung 2 cells (a variant of the MDA-MB-435 human breast cancer cell line) into the mammary fatpad.
- MDA-435-Lung 2 cells a variant of the MDA-MB-435 human breast cancer cell line
- the treatments were started, and repeated at 14 day intervals (day 24, 38, 52) for a total of three injections. Tumor measurements were taken weekly.
- the mice were killed on day 105 after tumor cell injection, .and the tumor weights .and incidence of metastasis recorded.
- the lungs were processed for histology, and single sections scored for the presence of micrometastases. The results are shown in Table 5.
- mice with 5 mm tumors at the time of therapy/number of mice injected b Mean weight of tumors (1SEM) c Number of tumors that had regressed at the time of autopsy d Number of mice with lung metastases, either macroscopic or microscopic/number of mice with tumors e p value from unpaired t test comparing tumor weight of treated mice with the control PG group.
- mice were injected i.p. with the human ovarian cancer cell line, SKOV3ipl. Five days after tumor injection, the mice were injected i.v. with the PG- paclitaxel (PG-TXL), at concentrations equivalent to 120 mg/kg or 160 mg/kg of paclitaxel. Initially the plan was to repeat these injections at 7-day intervals, but a single injection of the 160 mg/kg dose killed 5 of the 10 mice. Only the 120 mg/kg group received three injections. The study was terminated on day 98, and any surviving mice killed. The results are shown in FIG. 14, and in Table 6.
- PG-TXL PG- paclitaxel
- mice that dies within 5 days of the treatment f. the mouse that was killed on day 34 had minimal tumor burden, but was paraplegic (possible toxicity?).
- the PG-TXL 120 mg/kg significantly extended the survival of the mice with intraperitoneal SKOV3ipl, (a human ovarian cancer cell line which overexpresses HER2/neu), comp.ared with mice injected with PG alone. Multiple doses and/or increasing the dose of conjugate may significantly reduce the tumor incidence in addition to extending survival.
- SKOV3ipl a human ovarian cancer cell line which overexpresses HER2/neu
- the growth curves show that although breast cancer growth is checked by paclitaxel, especially with the higher dose conjugated with PG, tumor size continues to increase about a month after the therapy. A second (or third) round of therapy may have caused the tumor growth to plateau, or give more tumor regressions.
- the growth curves do not include the tumors that regressed - as shown in Table 4, the tumors shrank/disappeared in 50% of the mice treated with the 45
- paclitaxel 100 mg, 0.117 mmol
- dry DMF 2.2 ml
- DTPA A diethylenetriaminepentaacetic acid anhydride
- the reaction mixture was stirred at 4°C overnight.
- the suspension was filtered (0.2 ⁇ m Millipore filter) to remove unreacted DTPA anhydride.
- the filtrate was poured into distilled water, stirred at 4°C for 20 min, and the precipitate collected.
- the crude product was purified by preparative TLC over C 18 silica gel plates and developed in acetonitrile/water (1:1).
- Paclitaxel had an R f value of 0.34.
- the sodium salt of DTPA-paclitaxel was also obtained by adding a solution of
- Hydrolytic Stability of DTPA-Paclitaxel The hydrolytic stability of DTPA-paclitaxel was studied under accelerated conditions. Briefly, 1 mg of DTPA-paclitaxel was dissolved in 1 nil 0.5 M NaHC0 3 aqueous solution (pH 9.3) and analyzed by HPLC. The HPLC system consisted of a Waters 150 x 3.9 (i.d.) mm Nova-Pak column filled with C18 4 ⁇ m silica gel, a Perkin-Elmer isocratic LC pump, a PE Nelson 900 series interface, a Spectra-Physics UV/Vis detector and a data station.
- the retention times of DTPA-paclitaxel and paclitaxel were 1.38 and 8.83 min, respectively. Peak areas were quantitated and compared with standard curves to determine the DTPA-paclitaxel and paclitaxel concentrations.
- the estimated half-life of DTPA-paclitaxel in 0.5 M NaHC0 3 solution is about 16 days at room temperature.
- Cells were seeded in 24- well plates at a concentration of 2.5 x 10 cells/ml and grown in a 50:50 Dulbecco's modified minimal essential medium (DEM) and F12 medium containing 10% bovine calf serum at 37°C for 24 h in a 97% humidified atmosphere of 5.5% C0 2 . The medium was then replaced with fresh medium containing paclitaxel or DTPA-paclitaxel in concentration ranging from 5 x 10 " M to 75 x 10 " M. After 40 h, the cells were released by trypsinization and counted in a Coulter counter.
- DEM Dulbecco's modified minimal essential medium
- F12 medium containing 10% bovine calf serum at 37°C for 24 h in a 97% humidified atmosphere of 5.5% C0 2 .
- the medium was then replaced with fresh medium containing paclitaxel or DTPA-paclitaxel in concentration ranging from 5 x 10 " M to 75 x 10 " M. After 40
- DTPA-paclitaxel The effects of DTPA-paclitaxel on the growth of B16 melanoma cells are presented in FIG. 2. After a 40-h incubation with various concentrations, DTPA- 47 paclitaxel and paclitaxel were compared as to cytotoxicity.
- the IC 50 for paclitaxel and DTPA-paclitaxel are 15 nM and 7.5 nM, respectively.
- MCa-4 Mammary Carcinoma
- MCa-4 mammary carcinoma
- a single dose of paclitaxel or DTPA-paclitaxel was given at 10, 20 and 40 mg equivalent paclitaxel/kg body weight.
- saline and absolute alcohol/Cremophor 50/50 diluted with saline (1 :4) were used. Tumor growth was determined daily, by measuring three orthogonal tumor diameters. When the tumor size reached 12 mm in diameter, the tumor growth delay was calculated. The mice were sacrificed when tumors were approximately 15 mm.
- the tumor growth curve is shown in FIG. 3.
- both paclitaxel and DTPA-paclitaxel showed antitumor effect at a dose of 40 mg/kg.
- the data were also analyzed to determine the mean number of days for the tumor to reach 12 mm in diameter.
- Statistical analysis showed that DTPA-paclitaxel delayed tumor growth significantly compared to the saline treated control at a dose of 40 mg/kg (p ⁇ 0.01).
- the mean time for the tumor to reach 12 mm in diameter was 12.1 days for DTPA-paclitaxel compared to 9.4 days for paclitaxel (FIG. 4).
- HPLC HPLC was used to analyze the reaction mixture and purity of '"in-DTPA- paclitaxel.
- the system consisted of a LDC binary pump, a 100 x 8.0 mm (i.d.) Waters column filled with ODS 5 ⁇ m silica gel. The column was eluted at a flow rate of 1 ml/min with a gradient mixture of water and methanol (gradient from 0% to 85% methanol over 15 min). The gradient system was monitored with a Nal crystal detector and a Spectra-Physics UVNis detector.
- mice Female C3Hf/Kam mice were inoculated with mammary carcinoma (MCa-4) in the muscles of the right thigh (5 x 10 5 cells). When the tumors had grown to 12 mm in diameter, the mice were divided into two groups. In group I, the mice were anesthetized by intraperitoneal injection of sodium pentobarbital, followed by In- DTPA-paclitaxel (100-200 mCi) via tail vein. A ⁇ -camera equipped with a medium energy collimator was positioned over the mice (3 per group). A series of 5 min acquisitions were collected at 5, 30, 60, 120, 240 min and 24 h after injection. In group II, the same procedures were followed except that the mice were injected with mammary carcinoma (MCa-4) in the muscles of the right thigh (5 x 10 5 cells). When the tumors had grown to 12 mm in diameter, the mice were divided into two groups. In group I, the mice were anesthetized by intraperitoneal injection of sodium pentobarbital, followed
- FIG. 5 shows gamma-scintigraphs of .animals injected with
- U 1 U In-DTPA and ⁇ ⁇ In-DTPA-paclitaxel U 1 ln-DTPA was characterized by rapid clearance from the plasma, rapid and high excretion in the urine with minimal 49 retention in the kidney and negligible retention in the tumor, the liver, the intestine and other organs or body parts.
- In-DTPA-paclitaxel exhibited a pharmacological profile resembling that of paclitaxel (Eiseman et al, 1994). Radioactivity in the brain was negligible. Liver and kidney had the greatest tissue:plasma ratios. Hepatobiliary excretion of radiolabeled DTPA-paclitaxel or its metabolites was one of the major routes for the clearance of the drag from the blood.
- In-DTPA-paclitaxel Unlike paclitaxel, a significant amount of In-DTPA-paclitaxel was also excreted through kidney, which only played a minor role in the clearance of paclitaxel. The tumor had significant uptake of l In-DTPA-paclitaxel.
- In-DTPA-paclitaxel is able to detect certain tumors and to quantify the uptake of In-DTPA-paclitaxel in the tumors, which in turn, may assist in the selection of patients for the paclitaxel treatment.
- the smaller PG-TXL conjugate has a different distrubution than DTPA-paclitaxel, and partly localizes in the liver and tumors of test -animals.
- PEG-paclitaxel was synthesized by an N-ethoxycarbonyl-2-ethoxy-l,2-dihydroquinoline (EEDQ) mediated coupling reaction.
- EEDQ N-ethoxycarbonyl-2-ethoxy-l,2-dihydroquinoline
- PEG-Paclitaxel was dissolved in phosphate buffer (0.0 IM) at various pHs at a concentration of 0.4 mM and the solutions were allowed to incubate at 37°C with gentle shaking. At selected time intervals, aliquots (200 ⁇ l) were removed and lyophilized. The resulting dry powders were redissolved in methylene chloride for gel permeation chromatography (GPC analysis).
- GPC analysis gel permeation chromatography
- the GPC system consisted of a Perkin- Elmer PL gel mixed bed column, a Perkin-Elmer isocratic LC pump, a PE Nelson 900 series interface, a Spectra-Physics UVVis detector and a data station.
- the elutant (methylene chloride) was run at 1.0 ml/min with the UV detector set at 228 nm.
- the retention times of PEG-paclitaxel and paclitaxel were 6.1 and 8.2 min, respectively. Peak areas were quantified and the percentage of PEG-paclitaxel remaining and the percentage of paclitaxel released were calculated.
- the half life of PEG-paclitaxel determined by linear least-squares at pH 7.4 was 54 min.
- the half-life at pH 9.0 was 7.6 min. Release profiles of paclitaxel from PEG-paclitaxel at pH 7.4 is shown in FIG. 8.
- melanoma cells were seeded in 24-well plates at a concentration of 2.5 x 10 cells/ml and grown in a 50:50 Dulbecco's modified minimal essential medium (DME) .and F12 medium containing 10% bovine calf serum at 37°C for 24 h in a 97% humidified atmosphere of 5.5% C0 2 . The medium was then replaced with fresh medium containing paclitaxel or its derivatives in concentrations ranging from 5 10 " M to 75 x 10 "9 M. After 40 h, the cells were rele.ased by trypsinization .and 51
- MCa-4 cells (5 x 10 cells) were injected into the right thigh muscle of female C3Hf/Kam mice.
- a single dose of paclitaxel or PEG- paclitaxel was given at 10, 20 and at 40 mg equivalent paclitaxel/kg body weight.
- Paclitaxel was initially dissolved in absolute ethanol with an equal volume of Cremophor. This stock solution was further diluted (1:4 by volume) with a sterile physiological solution within 15 min of injection.
- PEG-paclitaxel was dissolved in saline (6 mg equiv. paclitaxel/ml) and filtered through a sterile filter (Millipore, 4.5 ⁇ m). Saline, paclitaxel vehicle, absolute alcoho Cremophor (1:1) diluted with saline (1 :4) and PEG solution in saline (600 mg/kg body weight) were used in control studies. Tumor growth was determined daily, by measuring three orthogonal tumor diameters. When the tumor size reached 12 mm in diameter, the tumor growth delay was calculated.
- the tumor growth curve is shown in FIG. 9.
- both PEG-paclitaxel and paclitaxel effectively delayed tumor growth.
- Paclitaxel was more effective th.an PEG-paclitaxel, although the difference w.as not statistically significant.
- Paclitaxel treated tumors required 9.4 days to reach 12 mm in diameter whereas PEG- paclitaxel-treated tumors required 8.5 days.
- these values were significant (p > 0.05) as compared to their corresponding controls, which were 6.7 days for the paclitaxel vehicle and 6.5 days for the saline solution of PEG (FIG. 4).
- the objective of this study was to compare PG-TXL and paclitaxel pharmacological properties in their ability to promote in vitro assembly of tubulin, to inhibit cell growth against rat mammary tumor cell line 13762F 'and hum.an breast tumor cell lines, to induce p53 protein, and to rescue a paclitaxel-dependent mutant cell line.
- Paclitaxel's release from PG-TXL in vivo was measured to determine if PG- TXL's mechanism of action can be attributed to free pacitaxel.
- paclitaxel PG-TXL
- PG-TXL PG-TXL
- aged PG-TXL were compared for their relative ability to promote in vitro assembly of purified bovine brain tubulin.
- the tubulin assembly reaction was performed at 32°C in PEM buffer (80 mM PIPES buffer, 1 mM EGTA, 1 mM MgCl 2 , pH 6.9) at a tubulin (bovine brain, Cytoskeleton Inc., Boulder, CO) concentration of 1 mg/ml (10 ⁇ M) in the presence or absence of drugs (1.0 ⁇ M equivalent paclitaxel) and 1.0 mM guanosine 5'-triphosphate (GTP).
- "Aged" PG-TXL was obtained by placing PG-TXL in PBS (pH 7.4) at 37°C for 3 days.
- Tubulin polymerization was followed by measuring the absorbance of the solution at 340 nm over time.
- PG-TXL and paclitaxel were compared for their ability to inhibit cell growth against the established rat mammary tumor cell line 13762F.
- the effect of PG-TXL on cell growth was examined by a-plating efficiency assay.
- Rat 13762F cells were seeded (200 cells) into 60 mm dishes containing drug concentrations varying from 0 to 200 nM in growth medium ( ⁇ modified minimum essential medium [ ⁇ -MEMJ containing 5% fetal bovine serum, 50 U/ml of penicillin, and 50 ⁇ g/ml of streptomycin).
- IC 50 50% inhibition of colony formation
- Tax 18 a CHO cell line selected for resistance to paclitaxel, is a well characterized mutant that has been found to require the continuous presence of paclitaxel for cell division.
- a -functional mitotic spindle apparatus is unable to form (Cabral et al, 1983).
- the mitosis phase of the cell cycle is prolonged with subsequent failure to segregate chromosomes and to divide into daughter cells. Nonetheless, the cells continue to progress through the cell cycle .and replicate their DNA resulting in the formation of large polyploid cells that eventually die due to genomic instability (Cabras and Barlow, 1991).
- paclitaxel-dependent CHO mutant Tax- 18 cells were carried out on 24-well tissue culture dishes. Approximately 100 cells were added to wells containing growth medium and equivalent concentrations of paclitaxel varying from 0 to 1.0 ⁇ M. After 6 days of incubation at 37°C, the medium was removed .and the cells were stained with methylene blue.
- mice normal female C3Hf/Kam mice (25-30 g) were injected with a dose of 20 mg equivalent [ HJpaclitaxel or PG-[ HJpaclitaxel intravenously into the tail vein. Each mouse received 6 ⁇ Ci of radiolabeled drug. [ HJpaclitaxel was dissolved in Cremophor EL® vehicle whereas PG-[ HJpaclitaxel was dissolved in saline. Volume injected into each mice was between 0.2 to 0.3 ml. At 0, 5, 15, 30 min, and 1, 2, 4, 8, 16, 24, 48 h postinjection, animals were sacrificed and blood samples were collected (4-5 mice per time point).
- mice bearing OCA-1 tumors were prepared as described previously. When the tumor reached 500 mm , animals were injected with a dose of 56
- aliquots of tissue homogenates were extracted with ethyl acetate and analyzed for free paclitaxel by HPLC.
- the HPLC system consisted of a 150x3.9 mm Nova-Pak column (Waters, Milford, MA), a liquid chromatography pump (Waters model 510), a UV/Vis detector set at 228 nm (Waters model 486), a flow scintillation analyzer (Packard model 500TR, Downers Grove, IL), and a Packard radiomatic software for data analysis.
- the uptake of total drugs in OCA-1 tumor was expressed as a percentage of the administered dose per gram of tissue and the association of radioactivity within OCA-1 tumor as free paclitaxel was expressed as dpm per gram tissue.
- Example 6 Effect of Polymer Structure on Activity of Water soluble polyamino Acid- Paclitaxel Conjugates.
- the present study evaluated whether antitumor activities of polymer-paclitaxel conjugates were affected by the structure of polyamino acids used for drug conjugation.
- Paclitaxel was coupled to poly(l-glutamic acid), poly(d-glutamic acid), and poly(l-aspartic acid) according to previously described procedures.
- These polyamino acid-paclitaxel conjugates had similar paclitaxel content, aqueous solubility, and molecular weight (30-40K).
- C3Hf/Kam mice bearing murine OCA- 1 ovarian cancer 500 mm at time of treatment
- poly(l-glutamic acid)-paclitaxel injection of poly(l-glutamic acid)-paclitaxel at 80 mg equiv. paclitaxel kg body weight produced a rumor growth delay of 21 days vs. saline treated controls.
- Poly(d-glutamic acid)-paclitaxel was as effective as poly(l-glutamic acid)-paclitaxel.
- paclitaxel conjugated with poly(l-aspartic acid) was completely inactive against OCA- 1 tumor.
- the antitumor activity of polymer-paclitaxel conjugates of different molecular weight IK, 13K, and 36K was compared. Conjugates of lower molecular weight were significantly less effective than conjugate of higher molecular weight. The .higher molecular weights above 50,000 was too viscous.
- mice were injected with either paclitaxel (80 mg/kg) or PG-TXL (160 mg equivalent paclitaxel/kg).
- paclitaxel 80 mg/kg
- PG-TXL 160 mg equivalent paclitaxel/kg
- tumors were histologically analyzed to quantify mitotic and apoptotic activity according to Milas et al. (1995).
- the mice were killed by cervical dislocation and the tumors were immediately excised -and placed in neutral-buffered formalin.
- the tissues were then processed and stained with hematoxylin and eosin. Both mitosis and apoptosis were scored in coded slides by microscopic examination at 400x magnification.
- mice The changes observed in the paclitaxel-treated mice were qualitatively similar to those previously described (Milas et al., 1995).
- the rumor cells showed marked nuclear fragmentation with formation of apoptotic bodies, which was especially marked on day 1 (FIG. 13).
- Viable tumor cell clumps with normal mitoses were still present in these tumors by 144 h, indicating that these tumors would eventually regrow.
- Treatment with PG-TXL only resulted in a mild increase in mitotically arrested cells and apoptotic cells, presumably due to the small amount of free paclitaxel released from PG-TXL (FIG. 13).
- tumors from PG-TXL-treated mice developed extensive edema and necrosis, and only a small rim of viable tumor cells remained.
- the residual tumor clumps as compared to controls were comprised of cells that were larger, more pleomorphic, and that displayed less mitotic activity.
- the content of CPT in the polymer conjugate was determined by fluorescence spectrometer (Perkin-Elmer Model MPF-44A) using emission wavelength of 430 nm and excitation wavelength of 370 nm. Content: 2% to 5% (w/w), solubility: >200 mg conjugate/ml.
- All accessible amine functional groups of poly-lysine will be converted to carboxylic acid functional groups by reacting poly-lysine with succinic anhydride, glutaric anhydride, or DTPA. The remaining unreacted NH2 group in poly-lysine will be blocked by reacting the modified polymer with acetic anhydride.
- TXL, docetaxel, other taxiods, etopside, teniposide, camptothecin, epothilone or other .anti-tumor drugs will be conjugated to the resulting polymer according to previously described procedures for the synthesis of PG-TXL.
- Polyamino acid copolymers containing glutamic acid may be synthesized by the copolymerization of N-carboxyanhydrides (NCAs) of corresponding amino acid with gamma-benzyl-L-glutamate NCA.
- NCAs N-carboxyanhydrides
- the resulting benzyl glutamate-containing 60 copolymer will be converted to glutamic acid-containing copolymer by removing the benzyl protecting group (FIG. 15).
- TXL, docetaxel, other taxiods, etopside, teniposide, camptothecin, epothilone or other anti-tumor drugs will be conjugated to the resulting polymer according to previously described procedures for the synthesis of PG-TXL and PG-CPT.
- Poly-L-glutamic acid-Paclitaxel is a conjugate of poly-L-glutamic acid and paclitaxel.
- This compound is water soluble and based on early animal studies it appears that it can be administered as a short, that is several minute, intravenous injection. Based on the in vitro .and early animal work, it appears that this compound is at least as active against cancer as the monomeric paclitaxel in Cremophor and may have fewer side effects. Based on these observations, this drug will be studied in humans. The study will first require formulation of this compound in a solvent which is commonly used for intravenous infusion.
- Phase I study of this drug will be performed using the starting dose defined in animal studies.
- the drug will be injected into the vein by a syringe over several min or alternatively it may be infused as a short infusion, up to approximately 10 to 15 min.
- the volume of the solvent will be from 10 ml to approximately 100 ml depending on which of the two intravenous injection approaches are used.
- the drug will be administered every 3 wk. This schedule is based on the early animal studies and on the schema used with paclitaxel in Cremophor. Three patients will be started on the lowest dose level as defined by the animal studies and will be treated with an injection of PG-TXL.
- Blood tests will be performed at baseline and weekly to evaluate blood counts; tests of liver function and renal function will be performed every 3 wk. It is expected that the counts and physiological parameters will recover sufficiently from the PG-TXL to resume the next cycle of treatment 3 wk after the previous one. If this is the case then the treatment will be repeated every 3 wk. If the first cohort of three patients tolerates the drug for 3 wk then these patients will be allowed to have the dose increased by a predetermined schema that is usually used in the Phase I studies. Once three patients have tolerated the first cycle, the next cohort of 3 patients will be started on the next higher dose level. This process of increasing the dose level will continue until at least 2 out of 3 patients at a dose level have side effects which are so severe that they prohibit continuing administration of the drug.
- the dose level just prior to the excessively toxic one will be considered the level of drug to be administered in subsequent studies.
- Six to ten patients shall be treated on the dose level which will be recommended for Phase II 62 studies to confirm its tolerability. Once the appropriate dose has been defined and acute toxic side effects of the drug evaluated, Phase II studies will be initiated.
- Phase II studies of PG-TXL will be performed in several tumor types. Each study will be designed in a usual standard Phase II manner following either Gahan's or Simon's design. In brief, approximately 14 patients of a given tumor type will be treated initially, if there is no evidence of anti-cancer activity in that tumor type then further studies of PG-TXL in that tumor type will be aborted. However, if at least one patient has clinical benefit, defined as at least 50% decrease in the sum of products of perpendicular cross-sectional diameters of the tumors, then the number of patients with that tumor type treated with PG-TXL will be increased to 30.
- the tumor types of special interest for PG-TXL will be the ones which have shown good response to paclitaxel and docetaxel. This will include ovarian cancer, breast cancer, and lung cancer.
- Studies comparing poly-glutamic acid-paclitaxel to paclitaxel in tumors showing response to PG-TXL will be performed. Such studies .are called Phase III studies.
- PG-TXL may be cost effective relative to paclitaxel monotherapy. Not only is the infusion going to be shorter, it is expected that in view of the absence of Cremophor fewer side effects will be experienced by the patients and therefore the 63 premedication regiment including steroids and intravenous H2 and HI blockers may no longer be necessary. All of these factors will result in a reduction in the cost of the treatment.
- Phase I studies may be completed in another 6 to 9 months. Once these have been completed, Phase
- Phase II studies in various tumor types may take another 6 to 9 months. At that point, the inventors will have a good idea of the efficacy of this drug and targeted Phase III studies may be designed and initiated. It is also possible that the Phase II studies will show enough clinical activity that abbreviated Phase III studies or no Phase III studies would be necessary.
- EXAMPLE 12 ENHANCEMENT OF TUMOR RADIORESPONSE OF A MURINE OVARIAN CARCINOMA BY POLY(L-GLUTAMIC ACID)-PACLITAXEL CONJUGATE
- mice were inoculated i.m. in the right hind leg with 5 x 10 5 ovarian OCa-1 carcinoma cells. When tumors reached 8 mm in diameter, mice were randomly divided into 12 groups with each group consisting of 6-12 mice. Mice in groups 1-5 were given saline, 14 Gy irradiation alone, or PG-TXL alone at doses of 47, 80 or 120 mg eq. paclitaxel/kg. Mice in groups 6-9 were given PG-TXL at 47 mg eq.
- PG-TXL paclitaxel/kg and 14 Gy local irradiation at 2, 24, 48, and 144 h after PG-TXL treatments.
- Group 10 was given PG- TXL at 80 mg eq. paclitaxel/kg and 14 Gy at 24 h after PG-TXL treatment.
- Groups 11 and 12 was given PG-TXL at 120 mg eq. paclitaxel kg and 14 Gy at 24 h prior or 24 h after PG-TXL treatment.
- PG-TXL was given in a single intravenous injection.
- Local gamma irradiation to the tumor was delivered from a 13 Cs irradiator at a dose rate of 7 Gy per minute. Tumor growth delay was determined by measuring three orthogonal tumor diameters until tumors reached 14 mm in diameter. 65
- the radiosensitization effects of PG-TXL were dose dependent. At the lower PG-TXL dose of 47 mg eq. paclitaxel/kg, a subadditive effect was observed.
- the mean enhancement factors varied from 0.54 to 0J5 depending on the timing of radiation delivery. However, a superadditive effect was observed at higher doses of PG-TXL.
- the mean enhancement factors increased from 0.75 to 1.8 and 4.2 when PG-TXL was given at 24 h prior to irradiation and PG-TXL doses were increased from 47 to 80 and 120 mg eq. paclitaxel/kg (Table 7).
- PG-TXL The subadditive effect of chemoradiation observed with PG-TXL at the lower dose may be attributed to inadequate cell killing and rapid repopulation of surviving cells.
- PG- TXL may have profound effects on population of cycling tumor cells and/or on tumor reoxygenation, resulting in significantly enhanced radiosensitization effect.
- PG-TXL when tumors were irradiated at 14 Gy prior to treatment with PG-TXL at 120 mg eq. paclitaxel/kg, a superadditive effect with an enhancement factor of 4.3 was observed (Table 7). This result contrasts with previous observation that paclitaxel induces radiation resistance when it was given after irradiation (Ingram and Redpath, 1997).
- Absolute growth delay is defined as the time in days for tumors in treated groups to grow from 8 to 14 mm minus the time in days for tumors in saline treated group to grow from 8 to 14 mm.
- Normalized growth delay is defined as the time in days for tumors to grow from 8 to 14 mm in mice treated with the combination of PG-TXL and radiation minus the time in days for tumors to grow from 8 to 14 mm in mice treated with PG-TXL alone.
- Enhancement factors are obtained by dividing normalized tumor growth delay in mice treated with PG-TXL plus radiation by the absolute growth delay in mice treated with radiation alone.
- the doses of radiation may be varied.
- Treatment schedules and dosages may be varied on a patient by patient basis, taking into account, for example, factors such as the weight and age of the patient, the type of tumor being treated, the severity of the disease condition, previous and/or concurrent therapeutic interventions, the manner of administration and the like, which can be readily determined by one of ordinary skill in the art.
- a preferred range of doses for PG-TXL would be from about 0.5 x to about 2 x the maximum tolerated dose of TXL in equivalent paclitaxel doses.
- the amount of PG-TXL administered may be spread over the course of radiation therapy as sub- doses.
- a preferred range of irradiation would be about 50 to about 70 Gray (Gy) administered over about 5 to about 7 weeks or about 10 Gray per week.
- Preferred schedules of administration would include administering PG- TXL about 1 to about 2 days before, or about 1 to about 2 days after irradiation.
- Schedules of administration of PG-TXL and other polymer-antitumor drug or chelator-antitumor drug compositions may be varied and/or repeated as determined by one of ordinary s ill in the art for the maximum benefit of each patient.
- compositions and methods of d are inventions in terms of prefeired embodiments, it will be apparent to those of skill in the .art that variations may be applied to the compositions, methods and in the steps or in the sequence of steps of the methods described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related, as other water soluble polymer-drug conjugates may be substituted for the agents described herein, the same or similar results would be achieved. All such similar substitutes and modifications 68
- Taxane Anticancer Agents Basic Science and Current Status, Georg, Chen, Ojima, Vyas, eds., American Chemical
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT99916188T ATE304867T1 (en) | 1998-03-30 | 1999-03-30 | WATER SOLUBLE PACLITAXEL CONJUGATES COMBINED WITH RADIATION FOR THE TREATMENT OF CANCER |
DE69927350T DE69927350T2 (en) | 1998-03-30 | 1999-03-30 | WATER-SOLUBLE PACLITAXEL CONJUGATE COMBINED WITH IRRADIATION TO TREAT CANCER |
EP99916188A EP1028756B1 (en) | 1998-03-30 | 1999-03-30 | Water soluble paclitaxel conjugates combined with irradiation for the treatment of cancer |
CA2303338A CA2303338C (en) | 1998-03-30 | 1999-03-30 | Water soluble paclitaxel derivatives |
AU34556/99A AU3455699A (en) | 1998-03-30 | 1999-03-30 | Water soluble paclitaxel derivatives |
US10/300,031 US6730699B2 (en) | 1998-03-30 | 2002-11-20 | Water soluble paclitaxel derivatives |
US11/253,810 US20060111273A1 (en) | 1998-03-30 | 2005-10-20 | Water soluble paclitaxel derivatives |
CY20051101376T CY1105547T1 (en) | 1998-03-30 | 2005-11-10 | WATER-SOLUBLE PACLITAXEL CONJUGATION COMBINED WITH RADIATION FOR CANCER TREATMENT |
US11/927,392 US20080153865A1 (en) | 1998-03-30 | 2007-10-29 | Water soluble paclitaxel derivatives |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/050,662 | 1998-03-30 | ||
US09/050,662 US6441025B2 (en) | 1996-03-12 | 1998-03-30 | Water soluble paclitaxel derivatives |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/050,662 Continuation US6441025B2 (en) | 1996-03-12 | 1998-03-30 | Water soluble paclitaxel derivatives |
US09/050,662 Continuation-In-Part US6441025B2 (en) | 1996-03-12 | 1998-03-30 | Water soluble paclitaxel derivatives |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09530601 A-371-Of-International | 2001-01-11 | ||
US10/153,818 Continuation US6515017B1 (en) | 1998-03-30 | 2002-05-24 | Water soluble paclitaxel derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999049901A1 true WO1999049901A1 (en) | 1999-10-07 |
Family
ID=21966621
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/006870 WO1999049901A1 (en) | 1998-03-30 | 1999-03-30 | Water soluble paclitaxel derivatives |
Country Status (12)
Country | Link |
---|---|
US (22) | US6441025B2 (en) |
EP (2) | EP1598081A3 (en) |
AT (1) | ATE304867T1 (en) |
AU (1) | AU3455699A (en) |
CA (1) | CA2303338C (en) |
CY (1) | CY1105547T1 (en) |
DE (1) | DE69927350T2 (en) |
DK (1) | DK1028756T3 (en) |
ES (1) | ES2249888T3 (en) |
MY (1) | MY121807A (en) |
TW (2) | TWI246922B (en) |
WO (1) | WO1999049901A1 (en) |
Cited By (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001026693A2 (en) * | 1999-10-12 | 2001-04-19 | Cell Therapeutics, Inc. | Manufacture of polyglutamate-therapeutic agent conjugates |
WO2001070275A2 (en) * | 2000-03-17 | 2001-09-27 | Cell Therapeutics, Inc. | Polyglutamic acid-camptothecin conjugates and methods of preparation |
EP1235598A2 (en) * | 1999-11-12 | 2002-09-04 | Angiotech Pharmaceuticals, Inc. | Compositions of a combination of radioactive therapy and cell-cycle inhibitors |
WO2003026718A1 (en) * | 2000-10-31 | 2003-04-03 | Cook Incorporated | Coated implantable medical device |
EP1311242A1 (en) * | 2000-08-22 | 2003-05-21 | New River Pharmaceuticals, Inc. | Active agent delivery systems and methods for protecting and administering active agents |
US6656966B2 (en) | 2000-06-22 | 2003-12-02 | Nitromed, Inc. | Nitrosated and nitrosylated taxanes, compositions and methods of use |
WO2004011034A1 (en) * | 2002-07-31 | 2004-02-05 | General Electric Company | Conjugated lysine copolymers for drug delivery and imaging |
EP1401374A1 (en) * | 2000-11-14 | 2004-03-31 | New River Pharmaceuticals Inc. | A novel pharmaceutical compound containing abacavir sulfate and methods of making and using same |
EP1475105A1 (en) * | 2003-05-09 | 2004-11-10 | Schering AG | Bone localising radiopharmaceutical and tubulin-interacting compound combinatorial radiotherapy |
WO2005079861A2 (en) * | 2004-02-13 | 2005-09-01 | Safeway Investments Ltd. | Polymeric water soluble prodrugs |
US7060724B2 (en) | 1996-03-12 | 2006-06-13 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
US7067111B1 (en) | 1999-10-25 | 2006-06-27 | Board Of Regents, University Of Texas System | Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging |
US7153864B2 (en) | 2000-03-17 | 2006-12-26 | Cell Therapeutics Inc. | Polyglutamic acid-camptothecin conjugates and methods of preparation |
AU2001298033B2 (en) * | 2000-11-14 | 2007-08-09 | Shire Llc | A novel pharmaceutical compound containing abacavir sulfate and methods of making and using same |
US7261875B2 (en) | 2001-12-21 | 2007-08-28 | Board Of Regents, The University Of Texas System | Dendritic poly (amino acid) carriers and methods of use |
CN100361985C (en) * | 2004-10-26 | 2008-01-16 | 中国科学院长春应用化学研究所 | Paclitaxol predrug of biodegradable polymer and its synthesis method |
CN100431610C (en) * | 2006-01-24 | 2008-11-12 | 中国科学院长春应用化学研究所 | Amphiphilic tri-block copolymer-paclitaxel bonded drug and preparation method thereof |
WO2009076272A2 (en) * | 2007-12-07 | 2009-06-18 | Boston Scientific Scimed, Inc. | Drug coated stent with endosome-disrupting conjugate |
EP2080511A2 (en) * | 2000-08-22 | 2009-07-22 | Shire LLC | Active agent delivery systems and methods for protecting and administering active agents |
US7846445B2 (en) | 2005-09-27 | 2010-12-07 | Amunix Operating, Inc. | Methods for production of unstructured recombinant polymers and uses thereof |
US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
US8557961B2 (en) | 2010-04-02 | 2013-10-15 | Amunix Operating Inc. | Alpha 1-antitrypsin compositions and methods of making and using same |
US8673860B2 (en) | 2009-02-03 | 2014-03-18 | Amunix Operating Inc. | Extended recombinant polypeptides and compositions comprising same |
US8680050B2 (en) | 2009-02-03 | 2014-03-25 | Amunix Operating Inc. | Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same |
US8703717B2 (en) | 2009-02-03 | 2014-04-22 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
US8716448B2 (en) | 2009-02-03 | 2014-05-06 | Amunix Operating Inc. | Coagulation factor VII compositions and methods of making and using same |
US8933197B2 (en) | 2007-08-15 | 2015-01-13 | Amunix Operating Inc. | Compositions comprising modified biologically active polypeptides |
US8957021B2 (en) | 2009-02-03 | 2015-02-17 | Amunix Operating Inc. | Glucose-regulating polypeptides and methods of making and using same |
US9050378B2 (en) | 2003-12-10 | 2015-06-09 | Board Of Regents, The University Of Texas System | N2S2 chelate-targeting ligand conjugates |
US9849188B2 (en) | 2009-06-08 | 2017-12-26 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
US9855338B2 (en) | 2005-12-05 | 2018-01-02 | Nitto Denko Corporation | Polyglutamate-amino acid conjugates and methods |
EP3372617A2 (en) | 2010-04-02 | 2018-09-12 | Amunix Operating Inc. | Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same |
US10172953B2 (en) | 2012-02-27 | 2019-01-08 | Amunix Operating Inc. | XTEN conjugate compositions and methods of making same |
US10370430B2 (en) | 2012-02-15 | 2019-08-06 | Bioverativ Therapeutics Inc. | Recombinant factor VIII proteins |
US10421798B2 (en) | 2012-02-15 | 2019-09-24 | Bioverativ Therapeutics Inc. | Factor VIII compositions and methods of making and using same |
US10548953B2 (en) | 2013-08-14 | 2020-02-04 | Bioverativ Therapeutics Inc. | Factor VIII-XTEN fusions and uses thereof |
US10745680B2 (en) | 2015-08-03 | 2020-08-18 | Bioverativ Therapeutics Inc. | Factor IX fusion proteins and methods of making and using same |
US10814013B2 (en) | 2006-10-05 | 2020-10-27 | The Board Of Regents Of The University Of Texas System | Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications |
US11713358B2 (en) | 2015-08-28 | 2023-08-01 | Amunix Pharmaceuticals, Inc. | Chimeric polypeptide assembly and methods of making and using the same |
Families Citing this family (275)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5439686A (en) * | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
US6774278B1 (en) | 1995-06-07 | 2004-08-10 | Cook Incorporated | Coated implantable medical device |
US8137684B2 (en) * | 1996-10-01 | 2012-03-20 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
US20050163818A1 (en) * | 1996-11-05 | 2005-07-28 | Hsing-Wen Sung | Drug-eluting device chemically treated with genipin |
WO1999001124A1 (en) * | 1996-12-03 | 1999-01-14 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US6204388B1 (en) * | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US6867305B2 (en) | 1996-12-03 | 2005-03-15 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US20050043376A1 (en) * | 1996-12-03 | 2005-02-24 | Danishefsky Samuel J. | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
US7407975B2 (en) * | 1997-08-09 | 2008-08-05 | Bayer Schering Pharma Ag | Epothilone derivatives, method for producing same and their pharmaceutical use |
US6241762B1 (en) | 1998-03-30 | 2001-06-05 | Conor Medsystems, Inc. | Expandable medical device with ductile hinges |
US20040254635A1 (en) | 1998-03-30 | 2004-12-16 | Shanley John F. | Expandable medical device for delivery of beneficial agent |
US7208010B2 (en) | 2000-10-16 | 2007-04-24 | Conor Medsystems, Inc. | Expandable medical device for delivery of beneficial agent |
US7713297B2 (en) * | 1998-04-11 | 2010-05-11 | Boston Scientific Scimed, Inc. | Drug-releasing stent with ceramic-containing layer |
US20030040790A1 (en) * | 1998-04-15 | 2003-02-27 | Furst Joseph G. | Stent coating |
US20020099438A1 (en) * | 1998-04-15 | 2002-07-25 | Furst Joseph G. | Irradiated stent coating |
US8070796B2 (en) | 1998-07-27 | 2011-12-06 | Icon Interventional Systems, Inc. | Thrombosis inhibiting graft |
US7967855B2 (en) * | 1998-07-27 | 2011-06-28 | Icon Interventional Systems, Inc. | Coated medical device |
YU57601A (en) * | 1999-02-11 | 2005-06-10 | Schering Aktiengesellschaft | Epothilon derivatives, method for the production and the use thereof as pharmaceuticals |
US20020058286A1 (en) * | 1999-02-24 | 2002-05-16 | Danishefsky Samuel J. | Synthesis of epothilones, intermediates thereto and analogues thereof |
US20040121954A1 (en) * | 1999-04-13 | 2004-06-24 | Xu Wuhan Jingya | Poly(dipeptide) as a drug carrier |
US7125893B1 (en) * | 1999-04-30 | 2006-10-24 | Schering Ag | 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations |
WO2001021219A2 (en) * | 1999-09-21 | 2001-03-29 | The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services | Imaging of drug accumulation as a guide to antitumor therapy |
US8236048B2 (en) | 2000-05-12 | 2012-08-07 | Cordis Corporation | Drug/drug delivery systems for the prevention and treatment of vascular disease |
GB0011903D0 (en) * | 2000-05-18 | 2000-07-05 | Astrazeneca Ab | Combination chemotherapy |
PL212211B1 (en) * | 2000-06-02 | 2012-08-31 | Regents Board Of | Ethylenedicysteine (ec)-drug conjugates |
JP5100951B2 (en) | 2000-09-29 | 2012-12-19 | コーディス・コーポレイション | Coated medical device |
US6764507B2 (en) | 2000-10-16 | 2004-07-20 | Conor Medsystems, Inc. | Expandable medical device with improved spatial distribution |
EP1582180B1 (en) | 2000-10-16 | 2008-02-27 | Conor Medsystems, Inc. | Expandable medical device for delivery of beneficial agent |
US6612976B2 (en) * | 2000-11-13 | 2003-09-02 | Isotech, L.L.C. | Radioactive medical devices and methods of making radioactive medical devices |
US6616592B1 (en) * | 2000-11-13 | 2003-09-09 | Isotech, L.L.C. | Radioactive medical devices for inhibiting a hyperplastic response and method of making radioactive medical devices |
US8394813B2 (en) | 2000-11-14 | 2013-03-12 | Shire Llc | Active agent delivery systems and methods for protecting and administering active agents |
CA2434566A1 (en) * | 2001-01-25 | 2002-08-15 | Timothy M. Malloy | Parenteral formulation containing epothilone analogs |
NZ526871A (en) * | 2001-01-25 | 2006-01-27 | Bristol Myers Squibb Co | Pharmaceutical dosage forms of epothilones for oral administration |
US20040073294A1 (en) | 2002-09-20 | 2004-04-15 | Conor Medsystems, Inc. | Method and apparatus for loading a beneficial agent into an expandable medical device |
DE10115740A1 (en) * | 2001-03-26 | 2002-10-02 | Ulrich Speck | Preparation for restenosis prophylaxis |
EP1389090A2 (en) * | 2001-04-26 | 2004-02-18 | Board of Regents, The University of Texas System | Diagnostic imaging compositions, their methods of synthesis and use |
US20030108585A1 (en) * | 2001-05-04 | 2003-06-12 | Roe R. Michael | Polymer conjugates of insecticidal peptides or nucleic acids or insecticides and methods of use thereof |
US8182527B2 (en) | 2001-05-07 | 2012-05-22 | Cordis Corporation | Heparin barrier coating for controlled drug release |
WO2003002243A2 (en) | 2001-06-27 | 2003-01-09 | Remon Medical Technologies Ltd. | Method and device for electrochemical formation of therapeutic species in vivo |
US7169752B2 (en) * | 2003-09-30 | 2007-01-30 | New River Pharmaceuticals Inc. | Compounds and compositions for prevention of overdose of oxycodone |
US20050025808A1 (en) * | 2001-09-24 | 2005-02-03 | Herrmann Robert A. | Medical devices and methods for inhibiting smooth muscle cell proliferation |
AU2002362836B2 (en) * | 2001-10-15 | 2008-05-22 | Crititech, Inc. | Compositions and methods for delivery of poorly water soluble drugs and methods of treatment |
US8435529B2 (en) | 2002-06-14 | 2013-05-07 | Immunomedics, Inc. | Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy |
US8877901B2 (en) * | 2002-12-13 | 2014-11-04 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
US7591994B2 (en) | 2002-12-13 | 2009-09-22 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
US9770517B2 (en) | 2002-03-01 | 2017-09-26 | Immunomedics, Inc. | Anti-Trop-2 antibody-drug conjugates and uses thereof |
ITMI20020680A1 (en) * | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | IMPROVED ANTI-TUMOR COMPOSITION BASED ON PACLITAXEL AND METHOD FOR ITS OBTAINING |
US8016881B2 (en) | 2002-07-31 | 2011-09-13 | Icon Interventional Systems, Inc. | Sutures and surgical staples for anastamoses, wound closures, and surgical closures |
US6921769B2 (en) | 2002-08-23 | 2005-07-26 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US7649006B2 (en) * | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
DE60330407D1 (en) | 2002-08-23 | 2010-01-14 | Sloan Kettering Inst Cancer | Synthesis of epothilones, intermediates thereof, analogs and their use |
US20040047835A1 (en) * | 2002-09-06 | 2004-03-11 | Cell Therapeutics, Inc. | Combinatorial drug therapy using polymer drug conjugates |
ES2377318T3 (en) | 2002-09-06 | 2012-03-26 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for the delivery of covalently bound therapeutic agents to them |
DE10244847A1 (en) | 2002-09-20 | 2004-04-01 | Ulrich Prof. Dr. Speck | Medical device for drug delivery |
WO2004044227A2 (en) * | 2002-11-07 | 2004-05-27 | Board Of Regents, The University Of Texas System | Ethylenedicysteine (ec)-drug conjugates, compositions and methods for tissue specific disease imaging |
US20040142014A1 (en) * | 2002-11-08 | 2004-07-22 | Conor Medsystems, Inc. | Method and apparatus for reducing tissue damage after ischemic injury |
EP1575638A1 (en) * | 2002-11-08 | 2005-09-21 | Conor Medsystems, Inc. | Expandable medical device and method for treating chronic total occlusions with local delivery of an angiogenic factor |
DK1585548T3 (en) | 2002-12-09 | 2018-09-03 | Abraxis Bioscience Llc | COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS |
JP4959136B2 (en) * | 2002-12-13 | 2012-06-20 | イミューノメディクス、インコーポレイテッド | Immunoconjugates with cleavable linkages in cells |
US8420086B2 (en) | 2002-12-13 | 2013-04-16 | Immunomedics, Inc. | Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases |
GB0305928D0 (en) * | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
WO2004087214A1 (en) | 2003-03-28 | 2004-10-14 | Conor Medsystems, Inc. | Implantable medical device with beneficial agent concentration gradient |
US20070092440A1 (en) * | 2003-05-09 | 2007-04-26 | Edgar Braendle | Bone localising radiopharmaceutical and tubulin-interacting compound combinatorial |
US7344491B1 (en) | 2003-11-26 | 2008-03-18 | Nanobiomagnetics, Inc. | Method and apparatus for improving hearing |
US7723311B2 (en) * | 2003-06-18 | 2010-05-25 | Nanobiomagnetics, Inc. | Delivery of bioactive substances to target cells |
US8651113B2 (en) * | 2003-06-18 | 2014-02-18 | Swr&D Inc. | Magnetically responsive nanoparticle therapeutic constructs and methods of making and using |
US7229979B2 (en) * | 2003-06-23 | 2007-06-12 | Immune Modulation, Inc. | Hypoestoxides, derivatives and agonists thereof for use as stent-coating agents |
US20050152979A1 (en) * | 2003-09-05 | 2005-07-14 | Cell Therapeutics, Inc. | Hydrophobic drug compositions containing reconstitution enhancer |
US7785653B2 (en) | 2003-09-22 | 2010-08-31 | Innovational Holdings Llc | Method and apparatus for loading a beneficial agent into an expandable medical device |
US20050148534A1 (en) * | 2003-09-22 | 2005-07-07 | Castellino Angelo J. | Small molecule compositions and methods for increasing drug efficiency using compositions thereof |
US7317070B1 (en) | 2004-03-12 | 2008-01-08 | Sigma-Aldrich Co. | Process for the preparation of polyamino acids |
MXPA06011420A (en) * | 2004-04-01 | 2007-04-20 | Cardiome Pharma Corp | Derivatives of ion channel modulating compounds and pharmaceutical compositions and uses thereof. |
US7754897B2 (en) * | 2005-06-15 | 2010-07-13 | Cardiome Pharma Corp. | Synthetic processes for the preparation of aminocyclohexyl ether compounds |
WO2005113011A2 (en) | 2004-04-01 | 2005-12-01 | Cardiome Pharma Corp. | Prodrugs of ion channel modulating compounds and uses thereof |
US7705036B2 (en) * | 2004-04-01 | 2010-04-27 | Cardiome Pharma Corp. | Deuterated aminocyclohexyl ether compounds and processes for preparing same |
CA3006109A1 (en) | 2004-05-03 | 2005-11-17 | Ipsen Biopharm Ltd. | Drug delivery liposomes containing anionic polyols or anionic sugars |
US8658203B2 (en) | 2004-05-03 | 2014-02-25 | Merrimack Pharmaceuticals, Inc. | Liposomes useful for drug delivery to the brain |
EP1802648A2 (en) * | 2004-09-10 | 2007-07-04 | Cornell Research Foundation, Inc. | Betulinol derivatives as anti-cancer agents |
WO2006035340A1 (en) * | 2004-09-27 | 2006-04-06 | Koninklijke Philips Electronics N.V. | Method for selecting the sensitivity of an input device |
AU2005294214A1 (en) * | 2004-10-07 | 2006-04-20 | Emory University | Multifunctional nanoparticles conjugates and their use |
US20050148669A1 (en) * | 2004-10-21 | 2005-07-07 | Daniel Amato | Amino acid esters as nutrient supplements and methods of use |
WO2006088525A1 (en) * | 2004-11-18 | 2006-08-24 | Cardiome Pharma Corp. | Synthetic process for aminocyclohexyl ether compounds |
CA2590515A1 (en) * | 2004-11-26 | 2006-06-01 | Stentomics Inc. | Chelating and binding chemicals to a medical implant, medical device formed, and therapeutic applications |
US20120269886A1 (en) | 2004-12-22 | 2012-10-25 | Nitto Denko Corporation | Therapeutic agent for pulmonary fibrosis |
PT2727583T (en) | 2004-12-22 | 2021-12-27 | Nitto Denko Corp | Drug carrier and drug carrier kit for inhibiting fibrosis |
US8377918B2 (en) * | 2005-01-31 | 2013-02-19 | ACC Therapeutics Inc | Apigenin for chemoprevention, and chemotherapy combined with therapeutic reagents |
US7850645B2 (en) * | 2005-02-11 | 2010-12-14 | Boston Scientific Scimed, Inc. | Internal medical devices for delivery of therapeutic agent in conjunction with a source of electrical power |
HUE038768T2 (en) | 2005-02-18 | 2018-11-28 | Abraxis Bioscience Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
US8323333B2 (en) * | 2005-03-03 | 2012-12-04 | Icon Medical Corp. | Fragile structure protective coating |
WO2006110197A2 (en) * | 2005-03-03 | 2006-10-19 | Icon Medical Corp. | Polymer biodegradable medical device |
US7452501B2 (en) * | 2005-03-03 | 2008-11-18 | Icon Medical Corp. | Metal alloy for a stent |
US7540995B2 (en) * | 2005-03-03 | 2009-06-02 | Icon Medical Corp. | Process for forming an improved metal alloy stent |
US20060200048A1 (en) * | 2005-03-03 | 2006-09-07 | Icon Medical Corp. | Removable sheath for device protection |
US20060201601A1 (en) * | 2005-03-03 | 2006-09-14 | Icon Interventional Systems, Inc. | Flexible markers |
WO2006096251A2 (en) * | 2005-03-03 | 2006-09-14 | Icon Medical Corp. | Improved metal alloys for medical device |
US20060264914A1 (en) * | 2005-03-03 | 2006-11-23 | Icon Medical Corp. | Metal alloys for medical devices |
US9107899B2 (en) | 2005-03-03 | 2015-08-18 | Icon Medical Corporation | Metal alloys for medical devices |
US9707302B2 (en) | 2013-07-23 | 2017-07-18 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
US10058621B2 (en) | 2015-06-25 | 2018-08-28 | Immunomedics, Inc. | Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers |
US9820986B2 (en) * | 2005-03-04 | 2017-11-21 | Taiwan Hopaz Chems, Mfg. Co., Ltd. | Glycopeptide compositions |
US20060258736A1 (en) * | 2005-05-12 | 2006-11-16 | Bristol-Myers Squibb Company | Dosing regimen |
EP1883627B1 (en) | 2005-05-18 | 2018-04-18 | Pharmascience Inc. | Bir domain binding compounds |
US20080206276A1 (en) | 2005-07-08 | 2008-08-28 | Michael Otto | Targeting Poly-Gamma-Glutamic Acid to Treat Staphylococcus Epidermidis and Related Infections |
EP1928435B8 (en) * | 2005-08-31 | 2019-03-20 | Abraxis BioScience, LLC | Compositions of poorly water soluble drugs with increased stability and methods for preparation thereof |
SI3311805T1 (en) | 2005-08-31 | 2020-07-31 | Abraxis Bioscience, Llc | Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents |
JP2009509535A (en) * | 2005-09-27 | 2009-03-12 | アムニクス, インコーポレイテッド | Proteinaceous drugs and their use |
US9839667B2 (en) | 2005-10-14 | 2017-12-12 | Allergan, Inc. | Prevention and treatment of ocular side effects with a cyclosporin |
US20070110786A1 (en) * | 2005-11-15 | 2007-05-17 | Boston Scientific Scimed, Inc. | Medical articles having enhanced therapeutic agent binding |
EP1957065A1 (en) * | 2005-12-06 | 2008-08-20 | Cell Therapeutics, Inc. | Estrogen cancer therapy |
WO2010009146A1 (en) * | 2008-07-15 | 2010-01-21 | University Of Kansas | Nanoclusters for delivery of poorly water soluble drug nanoparticles |
US8906392B2 (en) * | 2005-12-16 | 2014-12-09 | University Of Kansas | Nanocluster compositions and methods |
US9572886B2 (en) | 2005-12-22 | 2017-02-21 | Nitto Denko Corporation | Agent for treating myelofibrosis |
US20070148697A1 (en) * | 2005-12-27 | 2007-06-28 | Boston Scientific Scimed, Inc. | Methods and system for high throughput screening of polymer materials for medical devices |
US20070154466A1 (en) * | 2005-12-30 | 2007-07-05 | Jan Weber | Internal medical devices containing peroxide-converting catalysts |
US8834912B2 (en) * | 2005-12-30 | 2014-09-16 | Boston Scientific Scimed, Inc. | Medical devices having multiple charged layers |
US8840660B2 (en) | 2006-01-05 | 2014-09-23 | Boston Scientific Scimed, Inc. | Bioerodible endoprostheses and methods of making the same |
AR054215A1 (en) | 2006-01-20 | 2007-06-13 | Eriochem Sa | A PHARMACEUTICAL FORMULATION OF A TAXANE, A SOLID COMPOSITION OF A LIOFILIZED TAXAN FROM AN ACETIC ACID SOLUTION, A PROCEDURE FOR THE PREPARATION OF A SOLID COMPOSITION OF A TAXANE, A SOLUBILIZING COMPOSITION OF A LIOFILIZED TAXANE AND AN ELEMENTARY KIT |
US8440214B2 (en) * | 2006-01-31 | 2013-05-14 | Boston Scientific Scimed, Inc. | Medical devices for therapeutic agent delivery with polymeric regions that contain copolymers having both soft segments and uniform length hard segments |
US8089029B2 (en) | 2006-02-01 | 2012-01-03 | Boston Scientific Scimed, Inc. | Bioabsorbable metal medical device and method of manufacture |
US20070224235A1 (en) | 2006-03-24 | 2007-09-27 | Barron Tenney | Medical devices having nanoporous coatings for controlled therapeutic agent delivery |
US20070225800A1 (en) * | 2006-03-24 | 2007-09-27 | Sahatjian Ronald A | Methods and devices having electrically actuatable surfaces |
US8187620B2 (en) | 2006-03-27 | 2012-05-29 | Boston Scientific Scimed, Inc. | Medical devices comprising a porous metal oxide or metal material and a polymer coating for delivering therapeutic agents |
US8048150B2 (en) | 2006-04-12 | 2011-11-01 | Boston Scientific Scimed, Inc. | Endoprosthesis having a fiber meshwork disposed thereon |
US8758723B2 (en) | 2006-04-19 | 2014-06-24 | The Board Of Regents Of The University Of Texas System | Compositions and methods for cellular imaging and therapy |
NZ572836A (en) | 2006-05-16 | 2011-12-22 | Pharmascience Inc | Iap bir domain binding compounds |
KR100773029B1 (en) * | 2006-06-16 | 2007-11-05 | 이화여자대학교 산학협력단 | Water soluble micelle-forming and biodegradable cyclotriphosphazene-paclitaxol conjugate anticancer agent and the preparation method thereof |
US8815275B2 (en) | 2006-06-28 | 2014-08-26 | Boston Scientific Scimed, Inc. | Coatings for medical devices comprising a therapeutic agent and a metallic material |
CA2655793A1 (en) | 2006-06-29 | 2008-01-03 | Boston Scientific Limited | Medical devices with selective coating |
EP2054537A2 (en) * | 2006-08-02 | 2009-05-06 | Boston Scientific Scimed, Inc. | Endoprosthesis with three-dimensional disintegration control |
CA2662808A1 (en) | 2006-09-14 | 2008-03-20 | Boston Scientific Limited | Medical devices with drug-eluting coating |
CA2663220A1 (en) | 2006-09-15 | 2008-03-20 | Boston Scientific Limited | Medical devices and methods of making the same |
EP2081616B1 (en) | 2006-09-15 | 2017-11-01 | Boston Scientific Scimed, Inc. | Bioerodible endoprostheses and methods of making the same |
EP2210625B8 (en) | 2006-09-15 | 2012-02-29 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis with biostable inorganic layers |
WO2008034047A2 (en) | 2006-09-15 | 2008-03-20 | Boston Scientific Limited | Endoprosthesis with adjustable surface features |
JP2010503494A (en) | 2006-09-15 | 2010-02-04 | ボストン サイエンティフィック リミテッド | Biodegradable endoprosthesis and method for producing the same |
US8002821B2 (en) | 2006-09-18 | 2011-08-23 | Boston Scientific Scimed, Inc. | Bioerodible metallic ENDOPROSTHESES |
CA2663745A1 (en) * | 2006-09-18 | 2008-03-27 | Boston Scientific Limited | Medical devices |
PT2724722T (en) | 2006-10-20 | 2017-03-14 | Neurendo Pharma Llc | Method of restoring the incretin effect |
US8173686B2 (en) | 2006-11-06 | 2012-05-08 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
US8178564B2 (en) * | 2006-11-06 | 2012-05-15 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
US8168662B1 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
US8168661B2 (en) * | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
US7981150B2 (en) | 2006-11-09 | 2011-07-19 | Boston Scientific Scimed, Inc. | Endoprosthesis with coatings |
US20080276935A1 (en) | 2006-11-20 | 2008-11-13 | Lixiao Wang | Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
US8430055B2 (en) | 2008-08-29 | 2013-04-30 | Lutonix, Inc. | Methods and apparatuses for coating balloon catheters |
US8414525B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US9700704B2 (en) | 2006-11-20 | 2017-07-11 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US9737640B2 (en) | 2006-11-20 | 2017-08-22 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US8998846B2 (en) | 2006-11-20 | 2015-04-07 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US8414910B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US20080175887A1 (en) | 2006-11-20 | 2008-07-24 | Lixiao Wang | Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs |
US8414526B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids |
US8425459B2 (en) | 2006-11-20 | 2013-04-23 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent |
ES2506144T3 (en) | 2006-12-28 | 2014-10-13 | Boston Scientific Limited | Bioerodible endoprosthesis and their manufacturing procedure |
CN101209350B (en) | 2006-12-30 | 2011-09-07 | 中国人民解放军军事医学科学院毒物药物研究所 | Polyglutamate-medicament coupling compound with amino acid as communicating terminal |
WO2008089256A2 (en) * | 2007-01-16 | 2008-07-24 | Cappella, Inc. | Polymeric therapeutics |
US20080175881A1 (en) * | 2007-01-18 | 2008-07-24 | Boston Scientific Scimed, Inc. | Blood-contacting medical devices for the release of nitric oxide and anti-restenotic agents |
JP2010516625A (en) | 2007-01-24 | 2010-05-20 | インサート セラピューティクス, インコーポレイテッド | Polymer-drug conjugates with tether groups for controlled drug delivery |
US20080181852A1 (en) * | 2007-01-29 | 2008-07-31 | Nitto Denko Corporation | Multi-functional Drug Carriers |
US20110033528A1 (en) * | 2009-08-05 | 2011-02-10 | Poniard Pharmaceuticals, Inc. | Stabilized picoplatin oral dosage form |
US8070797B2 (en) | 2007-03-01 | 2011-12-06 | Boston Scientific Scimed, Inc. | Medical device with a porous surface for delivery of a therapeutic agent |
US8431149B2 (en) | 2007-03-01 | 2013-04-30 | Boston Scientific Scimed, Inc. | Coated medical devices for abluminal drug delivery |
EP2139469A4 (en) * | 2007-03-19 | 2011-09-07 | Inflabloc Pharmaceuticals Inc | Cobalamin taxane bioconjugates |
TWI407971B (en) | 2007-03-30 | 2013-09-11 | Nitto Denko Corp | Cancer cells and tumor-related fibroblasts |
US8067054B2 (en) | 2007-04-05 | 2011-11-29 | Boston Scientific Scimed, Inc. | Stents with ceramic drug reservoir layer and methods of making and using the same |
WO2008124735A2 (en) * | 2007-04-10 | 2008-10-16 | Nitto Denko Corporation | Multi-functional polyglutamate drug carriers |
JP2010528122A (en) * | 2007-05-09 | 2010-08-19 | 日東電工株式会社 | Polymer combined with platinum drug |
PT2155255E (en) | 2007-05-09 | 2013-10-15 | Nitto Denko Corp | Compositions that include a hydrophobic compound and a polyamino acid conjugate |
WO2008141110A2 (en) * | 2007-05-09 | 2008-11-20 | Nitto Denko Corporation | Polyglutamate conjugates and polyglutamate-amino acid conjugates having a plurality of drugs |
US7976915B2 (en) | 2007-05-23 | 2011-07-12 | Boston Scientific Scimed, Inc. | Endoprosthesis with select ceramic morphology |
TW200916094A (en) * | 2007-06-27 | 2009-04-16 | Poniard Pharmaceuticals Inc | Stabilized picoplatin dosage form |
US20100260832A1 (en) * | 2007-06-27 | 2010-10-14 | Poniard Pharmaceuticals, Inc. | Combination therapy for ovarian cancer |
US7942926B2 (en) | 2007-07-11 | 2011-05-17 | Boston Scientific Scimed, Inc. | Endoprosthesis coating |
US8002823B2 (en) | 2007-07-11 | 2011-08-23 | Boston Scientific Scimed, Inc. | Endoprosthesis coating |
EP2178893A4 (en) * | 2007-07-16 | 2012-09-19 | Poniard Pharmaceuticals Inc | Oral formulations for picoplatin |
EP2187988B1 (en) | 2007-07-19 | 2013-08-21 | Boston Scientific Limited | Endoprosthesis having a non-fouling surface |
US7931683B2 (en) * | 2007-07-27 | 2011-04-26 | Boston Scientific Scimed, Inc. | Articles having ceramic coated surfaces |
US8815273B2 (en) | 2007-07-27 | 2014-08-26 | Boston Scientific Scimed, Inc. | Drug eluting medical devices having porous layers |
WO2009018340A2 (en) | 2007-07-31 | 2009-02-05 | Boston Scientific Scimed, Inc. | Medical device coating by laser cladding |
EP2185103B1 (en) | 2007-08-03 | 2014-02-12 | Boston Scientific Scimed, Inc. | Coating for medical device having increased surface area |
US8052745B2 (en) | 2007-09-13 | 2011-11-08 | Boston Scientific Scimed, Inc. | Endoprosthesis |
WO2009036368A2 (en) | 2007-09-14 | 2009-03-19 | Nitto Denko Corporation | Drug carriers |
AR063111A1 (en) | 2007-10-03 | 2008-12-30 | Eriochem Sa | A PHARMACEUTICAL FORMULATION OF TAXANO |
JP5308447B2 (en) * | 2007-10-16 | 2013-10-09 | バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド | C10-substituted camptothecin analogs |
US8216632B2 (en) | 2007-11-02 | 2012-07-10 | Boston Scientific Scimed, Inc. | Endoprosthesis coating |
US8029554B2 (en) | 2007-11-02 | 2011-10-04 | Boston Scientific Scimed, Inc. | Stent with embedded material |
US7938855B2 (en) * | 2007-11-02 | 2011-05-10 | Boston Scientific Scimed, Inc. | Deformable underlayer for stent |
US8101706B2 (en) | 2008-01-11 | 2012-01-24 | Serina Therapeutics, Inc. | Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same |
WO2009099651A1 (en) * | 2008-02-08 | 2009-08-13 | Poniard Pharmaceuticals, Inc. | Use of picoplatin and cetuximab to treat colorectal cancer |
JP2011513412A (en) * | 2008-03-06 | 2011-04-28 | 日東電工株式会社 | Pharmaceutical composition for treating cancer comprising a polymer paclitaxel conjugate |
WO2009131911A2 (en) | 2008-04-22 | 2009-10-29 | Boston Scientific Scimed, Inc. | Medical devices having a coating of inorganic material |
WO2009132176A2 (en) | 2008-04-24 | 2009-10-29 | Boston Scientific Scimed, Inc. | Medical devices having inorganic particle layers |
US7998192B2 (en) | 2008-05-09 | 2011-08-16 | Boston Scientific Scimed, Inc. | Endoprostheses |
EP2303288A4 (en) | 2008-05-22 | 2015-04-22 | Univ Ramot | Conjugates of a polymer, a bisphosphonate and an anti-angiogenesis agent and uses thereof in the treatment and monitoring of bone related diseases |
WO2009141826A2 (en) | 2008-05-22 | 2009-11-26 | Ramot At Tel Aviv University Ltd. | Novel conjugates of polymers having a therapeutically active agent and an angiogenesis targeting moiety attached thereto and uses thereof in the treatment of angiogenesis related diseases |
US8703114B2 (en) * | 2008-05-22 | 2014-04-22 | Ramot At Tel-Aviv University Ltd. | Conjugate of a polymer, an anti-angiogenesis agent and a targeting moiety, and uses thereof in the treatment of bone related angiogenesis conditions |
US20090297581A1 (en) * | 2008-05-28 | 2009-12-03 | Boston Scientific Scimed, Inc. | Medical devices having electrodeposited coatings |
US8236046B2 (en) * | 2008-06-10 | 2012-08-07 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis |
EP2303350A2 (en) | 2008-06-18 | 2011-04-06 | Boston Scientific Scimed, Inc. | Endoprosthesis coating |
WO2009158325A2 (en) * | 2008-06-25 | 2009-12-30 | Boston Scientific Scimed, Inc. | Medical devices having surface coatings |
EP2307069A2 (en) * | 2008-06-25 | 2011-04-13 | Boston Scientific Scimed, Inc. | Medical devices for delivery of therapeutic agent in conjunction with galvanic corrosion |
US20090324685A1 (en) * | 2008-06-26 | 2009-12-31 | Boston Scientific Scimed, Inc. | Medical device coatings containing charged materials |
TW201004646A (en) * | 2008-07-30 | 2010-02-01 | Nitto Denko Corp | Drug carriers |
US7985252B2 (en) | 2008-07-30 | 2011-07-26 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis |
US8399600B2 (en) * | 2008-08-07 | 2013-03-19 | Sigma-Aldrich Co. Llc | Preparation of low molecular weight polylysine and polyornithine in high yield |
EP2323709A2 (en) | 2008-08-14 | 2011-05-25 | Boston Scientific Scimed, Inc. | Medical devices having electrodeposited conductive polymer coatings |
US8382824B2 (en) | 2008-10-03 | 2013-02-26 | Boston Scientific Scimed, Inc. | Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides |
US8231980B2 (en) | 2008-12-03 | 2012-07-31 | Boston Scientific Scimed, Inc. | Medical implants including iridium oxide |
DK3903829T3 (en) | 2009-02-13 | 2023-06-26 | Immunomedics Inc | IMMUNE CONJUGATES WITH AN INTRACELLULAR CLEAVABLE BOND |
EP2403546A2 (en) | 2009-03-02 | 2012-01-11 | Boston Scientific Scimed, Inc. | Self-buffering medical implants |
US8071156B2 (en) | 2009-03-04 | 2011-12-06 | Boston Scientific Scimed, Inc. | Endoprostheses |
US8287937B2 (en) | 2009-04-24 | 2012-10-16 | Boston Scientific Scimed, Inc. | Endoprosthese |
US20120225825A1 (en) * | 2009-11-23 | 2012-09-06 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutic delivery |
EP2519269A1 (en) | 2009-12-30 | 2012-11-07 | Boston Scientific Scimed, Inc. | Drug-delivery balloons |
CN103002919B (en) * | 2010-02-04 | 2015-03-25 | 得克萨斯系统大学评议会 | Tumor targeted delivery of immunomodulators by nanoplymers |
US8702682B2 (en) * | 2010-02-05 | 2014-04-22 | Boston Scientific Scimed, Inc. | Medical devices employing piezoelectric materials for delivery of therapeutic agents |
EP2534170B1 (en) | 2010-02-12 | 2017-04-19 | Pharmascience Inc. | Iap bir domain binding compounds |
US8398916B2 (en) | 2010-03-04 | 2013-03-19 | Icon Medical Corp. | Method for forming a tubular medical device |
AR093275A1 (en) | 2010-03-17 | 2015-05-27 | Centro De Excelencia En Productos Y Procesos De Cordoba (Ceprocor) | A PHARMACEUTICAL COMPOSITION SOLUBLE IN WATER THAT INCLUDES AT LEAST A THERAPEUTICALLY ACTIVE SUBSTANCE OF HYDROPHOBIC CHARACTERISTICS AND AT LEAST A SELECTED COMPOSITE BETWEEN THE SYMPHOGLIOPHYMPHYLOPHYLOPHYLOPHYLOPHYLOPHYLOPHYLOPHYLOPHYLOPHYLOPHYLOPHYL SOPHYLOPHYLOPHYLOPHYLOSPHYLOPHYLOPHYLOPHYL SINGLE WATER SOLUBLE COMPOSITION IN A WATER SOLUBLE PHARMACEUTICAL COMPOSITION THAT INCLUDES AT LEAST A THERAPEUTICALLY ACTIVE SUBSTANCE OF HYDROPHOBIC CHARACTERISTICS AND AT LEAST A SELECTED COMPOSITE |
US8668732B2 (en) | 2010-03-23 | 2014-03-11 | Boston Scientific Scimed, Inc. | Surface treated bioerodible metal endoprostheses |
MX369728B (en) | 2010-03-29 | 2019-11-20 | Abraxis Bioscience Llc | Methods of enhancing drug delivery and effectiveness of therapeutic agents. |
CA2793974A1 (en) | 2010-03-29 | 2011-10-06 | Abraxis Bioscience, Llc | Methods of treating cancer |
DE102010022588A1 (en) | 2010-05-27 | 2011-12-01 | Hemoteq Ag | Balloon catheter with a particle-free drug-releasing coating |
CN106924219A (en) | 2010-06-04 | 2017-07-07 | 阿布拉科斯生物科学有限公司 | The method for treating cancer of pancreas |
US9283279B2 (en) | 2011-05-11 | 2016-03-15 | Ramot At Tel-Aviv University Ltd. | Targeted polymeric conjugates and uses thereof |
AU2012352149B2 (en) | 2011-12-13 | 2017-06-01 | Io Therapeutics, Inc. | Autoimmune disorder treatment using RXR agonists |
WO2013119864A1 (en) | 2012-02-07 | 2013-08-15 | University Of Central Florida Research Foundation, Inc. | Increasing taxane sensitivity in cancer cells |
WO2013131105A1 (en) * | 2012-03-02 | 2013-09-06 | Sri International | Synergistic anti-proliferation activity of tas-108 with mtor inhibitors against cancer cells |
EP2822598A4 (en) | 2012-03-05 | 2016-04-13 | Univ Ramot | Polymers having therapeutically active agents conjugated thereto, processes of preparing same and uses thereof |
CN102558270A (en) * | 2012-03-09 | 2012-07-11 | 辽宁新中现代医药有限公司 | 20(S) and 20(R)-dammarane-3beta,12beta,20,25-tetrol derivative and preparation method and application thereof |
CN104168927B (en) | 2012-03-27 | 2016-10-05 | 泰尔茂株式会社 | Coating composition and medical apparatus and instruments |
WO2013152227A1 (en) * | 2012-04-06 | 2013-10-10 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Embelin-based delivery system for water-insoluble active agents |
RU2493848C1 (en) * | 2012-06-14 | 2013-09-27 | Геннадий Петрович Власов | Biodegradable polymer carrier for anti-cancer drug delivery (versions) |
US9382329B2 (en) | 2012-08-14 | 2016-07-05 | Ibc Pharmaceuticals, Inc. | Disease therapy by inducing immune response to Trop-2 expressing cells |
GB201215289D0 (en) * | 2012-08-28 | 2012-10-10 | Medical Res Council | Nanoparticle formulation |
WO2014055493A1 (en) | 2012-10-02 | 2014-04-10 | Cerulean Pharma Inc. | Methods and systems for polymer precipitation and generation of particles |
CN103808852A (en) * | 2012-11-15 | 2014-05-21 | 刘胜远 | Thin-layer chromatography detection method of taxol in taxus chinensis |
CN103641925B (en) * | 2012-11-27 | 2016-08-17 | 王晖 | Water solublity polysaccharide and the covalency polyacetylene compound of bearing taxanes, its preparation method and medical usage |
US10744129B2 (en) | 2012-12-13 | 2020-08-18 | Immunomedics, Inc. | Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2 |
US10413539B2 (en) | 2012-12-13 | 2019-09-17 | Immunomedics, Inc. | Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132) |
US10206918B2 (en) | 2012-12-13 | 2019-02-19 | Immunomedics, Inc. | Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers |
HUE057977T2 (en) | 2012-12-13 | 2022-06-28 | Immunomedics Inc | Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity |
US9931417B2 (en) | 2012-12-13 | 2018-04-03 | Immunomedics, Inc. | Antibody-SN-38 immunoconjugates with a CL2A linker |
US9492566B2 (en) | 2012-12-13 | 2016-11-15 | Immunomedics, Inc. | Antibody-drug conjugates and uses thereof |
WO2015012904A2 (en) | 2012-12-13 | 2015-01-29 | Immunomedics, Inc. | Antibody-sn-38 immunoconjugates with a cl2a linker |
US10137196B2 (en) | 2012-12-13 | 2018-11-27 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity |
US11253606B2 (en) | 2013-07-23 | 2022-02-22 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
US10300070B2 (en) | 2014-03-27 | 2019-05-28 | The Brigham And Women's Hospital, Inc. | Metabolically-activated drug conjugates to overcome resistance in cancer therapy |
EP3160397A4 (en) | 2014-06-24 | 2018-03-21 | Icon Medical Corp. | Improved metal alloys for medical devices |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
CN104434808A (en) | 2014-07-03 | 2015-03-25 | 石药集团中奇制药技术(石家庄)有限公司 | Therapeutic nanoparticles and preparation method thereof |
KR101616623B1 (en) * | 2014-07-24 | 2016-04-29 | 연세대학교 산학협력단 | Nanoparticle comprising hydrophobic drug conjugated to cationic polymer and hydrophilic drug conjugated to anionic polymer |
US10034871B2 (en) | 2014-11-07 | 2018-07-31 | Regents Of The University Of Minnesota | Salts and compositions useful for treating disease |
AR100034A1 (en) | 2015-01-30 | 2016-09-07 | Consejo Nac De Investig Científicas Y Técnicas (Conicet) | A PHARMACEUTICAL COMPOSITION SOLUBLE IN WATER THAT INCLUDES, AT LEAST, A THERAPEUTICALLY ACTIVE SUBSTANCE AND, AT LEAST, A CAPACITY SUBSTANCE TO FORM MICELAS |
CA2981543A1 (en) | 2015-04-22 | 2016-10-27 | Immunomedics, Inc. | Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells |
US10195175B2 (en) | 2015-06-25 | 2019-02-05 | Immunomedics, Inc. | Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors |
SG10201912568PA (en) | 2015-10-16 | 2020-02-27 | Ipsen Biopharm Ltd | Stabilizing camptothecin pharmaceutical compositions |
EP3397276A4 (en) | 2015-12-30 | 2019-12-18 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
US20170224837A1 (en) | 2016-02-10 | 2017-08-10 | Immunomedics, Inc. | Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers |
US11766506B2 (en) | 2016-03-04 | 2023-09-26 | Mirus Llc | Stent device for spinal fusion |
IL261669B2 (en) | 2016-03-10 | 2023-12-01 | Io Therapeutics Inc | Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones |
KR102420468B1 (en) | 2016-03-14 | 2022-07-13 | 위스콘신 얼럼나이 리서어치 화운데이션 | Oligolactic acid conjugate and micelles with improved anticancer efficacy |
RU2725292C2 (en) | 2016-04-27 | 2020-06-30 | Иммьюномедикс, Инк. | Efficacy of conjugates of anti-trop-2 antibody with drug sn-38 for therapy of recurrent/refractory to inhibitors of tumor control point |
SG10201609131YA (en) | 2016-11-01 | 2018-06-28 | Xylonix Ip Holdings Pte Ltd | Zinc-pga compositions and methods for treating cancer |
US10888553B2 (en) * | 2016-11-14 | 2021-01-12 | Karlsson-Tuner Invest As | Use of non-transition metal coordinated dipyridoxyl compounds to prevent and treat chemotherapy-induced PSN |
JP2020512314A (en) | 2017-03-27 | 2020-04-23 | イミューノメディクス、インコーポレイテッドImmunomedics, Inc. | Treatment of Trop-2-expressing triple-negative breast cancer with sacituzumab gobitecan and RAD51 inhibitor |
EP3606964A4 (en) | 2017-04-03 | 2020-12-09 | Immunomedics, Inc. | Subcutaneous administration of antibody-drug conjugates for cancer therapy |
IT201700067430A1 (en) * | 2017-06-16 | 2018-12-16 | Consiglio Nazionale Ricerche | Nanoparticles as vehicles for the release of active ingredients and methods for their production |
AU2018335393A1 (en) | 2017-09-20 | 2020-04-02 | Io Therapeutics, Inc. | Treatment of disease with esters of selective RXR agonists |
AU2018350825A1 (en) * | 2017-10-16 | 2020-05-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Macromolecular platform for targeting scavenger receptor A1 |
EP4041312A4 (en) | 2019-10-10 | 2023-12-20 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
EP4069214A4 (en) * | 2019-12-03 | 2023-11-22 | Onselex Pharmaceuticals, Inc. | Polyphosphazene drug carriers |
US20240043615A1 (en) * | 2020-12-04 | 2024-02-08 | The Methodist Hospital System | Amino acid polymer-platinum anticancer drug conjugates |
WO2023108012A1 (en) | 2021-12-07 | 2023-06-15 | Io Therapeutics, Inc. | Use of an rxr agonist and taxanes in treating her2+ cancers |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5473055A (en) * | 1992-06-19 | 1995-12-05 | Farmitalia Carlo Erba S.R.L. | Polymer-bound paclitaxel derivatives |
US5626862A (en) * | 1994-08-02 | 1997-05-06 | Massachusetts Institute Of Technology | Controlled local delivery of chemotherapeutic agents for treating solid tumors |
US5730968A (en) * | 1994-03-31 | 1998-03-24 | Sterling Winthrop Inc. | Segmented chelating polymers as imaging and therapeutic agents |
Family Cites Families (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US155992A (en) * | 1874-10-13 | Improvement in iron pavements | ||
US34363A (en) * | 1862-02-11 | Improvement in machinery for cleaning cotton | ||
US41189A (en) * | 1864-01-12 | Improvement in adjusting logs in saw-mills | ||
US545880A (en) * | 1895-09-10 | Cotton chopper and cultivator | ||
US507659A (en) * | 1893-10-31 | Gottfried knoche | ||
US16285A (en) * | 1856-12-23 | Manufacture op hosiery | ||
US564159A (en) * | 1896-07-14 | Railway-switch | ||
GB1064417A (en) * | 1963-12-09 | 1967-04-05 | Kyowa Hakko Kogyo Kk | Process for the preparation of copolypeptides |
GB1541435A (en) * | 1975-02-04 | 1979-02-28 | Searle & Co | Immunological materials |
FR2398348A1 (en) * | 1977-07-20 | 1979-02-16 | Ferodo Sa | POSITIONING DEVICE |
US4356166A (en) * | 1978-12-08 | 1982-10-26 | University Of Utah | Time-release chemical delivery system |
US4343579A (en) * | 1979-09-07 | 1982-08-10 | Signode Corporation | Nail stack |
US4485093A (en) * | 1982-08-13 | 1984-11-27 | Runge Richard G | Immunotoxin conjugate which comprises arsanilic acid, useful for treating malignant tumors, particularly pancreatic cancer |
JPS59186924A (en) * | 1983-04-08 | 1984-10-23 | Kureha Chem Ind Co Ltd | Antitumor agent bonded with human immunoglobulin |
EP0150184A1 (en) * | 1983-07-01 | 1985-08-07 | Battelle Memorial Institute | Biodegradable polypeptide and utilization thereof for the progressive release of drugs |
CA1309558C (en) * | 1986-05-30 | 1992-10-27 | Quidel | D-gl conjugate therapy |
US4950713A (en) * | 1986-05-30 | 1990-08-21 | La Jolla Pharmaceutical Company | Conjugates of D-glutamic acid: D-lysine copolymer and certain biochemicals |
IN165717B (en) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
US5340817A (en) * | 1987-04-14 | 1994-08-23 | Research Triangle Institute | Method of treating tumors with anti-tumor effective camptothecin compounds |
JPS6461422A (en) | 1987-09-02 | 1989-03-08 | Nippon Kayaku Kk | Water-soluble polymeric carcinostatic agent |
JPS6461423A (en) | 1987-09-02 | 1989-03-08 | Nippon Kayaku Kk | Water-soluble polymeric carcinostatic agent |
US4943579A (en) * | 1987-10-06 | 1990-07-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Water soluble prodrugs of camptothecin |
US4942184A (en) | 1988-03-07 | 1990-07-17 | The United States Of America As Represented By The Department Of Health And Human Services | Water soluble, antineoplastic derivatives of taxol |
US5169933A (en) | 1988-08-15 | 1992-12-08 | Neorx Corporation | Covalently-linked complexes and methods for enhanced cytotoxicity and imaging |
US4960790A (en) | 1989-03-09 | 1990-10-02 | University Of Kansas | Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof |
JP2517760B2 (en) * | 1989-05-11 | 1996-07-24 | 新技術事業団 | Water-soluble polymerized pharmaceutical preparation |
US5162515A (en) * | 1990-01-16 | 1992-11-10 | La Jolla Pharmaceutical Company | Conjugates of biologically stable polymers and polynucleotides for treating systemic lupus erythematosus |
FR2658076B1 (en) * | 1990-02-12 | 1992-06-12 | Sanofi Sa | COSMETIC COMPOSITION CONTAINING COPOLYMERS OF AMINO ACIDS, USEFUL AS A MOISTURIZING AGENT. |
US5357827A (en) * | 1990-03-15 | 1994-10-25 | Abbott Laboratories | Torque compensated cam assembly and method |
US5219564A (en) | 1990-07-06 | 1993-06-15 | Enzon, Inc. | Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon |
US5059699A (en) | 1990-08-28 | 1991-10-22 | Virginia Tech Intellectual Properties, Inc. | Water soluble derivatives of taxol |
JP3310000B2 (en) | 1990-11-07 | 2002-07-29 | 靖久 桜井 | Water-soluble polymer anticancer agent and carrier for drug support |
US5811447A (en) | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6515009B1 (en) | 1991-09-27 | 2003-02-04 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
JPH05117385A (en) | 1991-10-31 | 1993-05-14 | Res Dev Corp Of Japan | Production of block copolymer, block copolymer and water-soluble polymeric carcinostatic agent |
DE4138042C2 (en) | 1991-11-19 | 1993-10-14 | Biotechnolog Forschung Gmbh | Epothilones, their production processes and agents containing these compounds |
US5272171A (en) | 1992-02-13 | 1993-12-21 | Bristol-Myers Squibb Company | Phosphonooxy and carbonate derivatives of taxol |
DE69329073T2 (en) * | 1992-03-23 | 2001-01-18 | Georgetown University Washingt | TAXOL ENCLOSED IN LIPOSOMES AND METHOD OF USE |
JPH05286868A (en) | 1992-04-03 | 1993-11-02 | Kiyoshi Okawa | Carcinostatic agent complex and its screening method |
US5312922A (en) * | 1992-04-06 | 1994-05-17 | Nordion International Inc. | Europium and terbium chelators for time-resolved fluorometric assays |
WO1993024476A1 (en) | 1992-06-04 | 1993-12-09 | Clover Consolidated, Limited | Water-soluble polymeric carriers for drug delivery |
CA2086874E (en) | 1992-08-03 | 2000-01-04 | Renzo Mauro Canetta | Methods for administration of taxol |
US5614549A (en) | 1992-08-21 | 1997-03-25 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
WO1994005203A1 (en) * | 1992-09-04 | 1994-03-17 | The General Hospital Corporation | Biocompatible polymers containing diagnostic or therapeutic moieties |
WO1994005282A1 (en) | 1992-09-04 | 1994-03-17 | The Scripps Research Institute | Water soluble taxol derivatives |
US5871710A (en) * | 1992-09-04 | 1999-02-16 | The General Hospital Corporation | Graft co-polymer adducts of platinum (II) compounds |
DE4231408A1 (en) | 1992-09-19 | 1994-03-24 | Schleicher & Co Int | Device for shredding documents |
US5489525A (en) | 1992-10-08 | 1996-02-06 | The United States Of America As Represented By The Department Of Health And Human Services | Monoclonal antibodies to prostate cells |
FR2697752B1 (en) * | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Antitumor compositions containing taxane derivatives. |
US5380751A (en) | 1992-12-04 | 1995-01-10 | Bristol-Myers Squibb Company | 6,7-modified paclitaxels |
MX9308012A (en) | 1992-12-24 | 1994-08-31 | Bristol Myers Squibb Co | PHOSPHONOOXIMETHYL ETHER OF TAXANE DERIVATIVES, SOLUBLE IN WATER AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM. |
US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
WO1994017829A1 (en) | 1993-02-02 | 1994-08-18 | Neorx Corporation | Directed biodistribution of small molecules |
US5468769A (en) | 1993-07-15 | 1995-11-21 | Abbott Laboratories | Paclitaxel derivatives |
ATE154757T1 (en) | 1993-07-19 | 1997-07-15 | Angiotech Pharm Inc | ANTI-ANGIogenic AGENTS AND METHODS OF USE THEREOF |
US5716981A (en) | 1993-07-19 | 1998-02-10 | Angiogenesis Technologies, Inc. | Anti-angiogenic compositions and methods of use |
DK0727223T3 (en) * | 1993-09-28 | 2002-02-11 | Hisamitsu Pharmaceutical Co | Polyamino acid-oligonucleotidbærer |
GB9320781D0 (en) * | 1993-10-08 | 1993-12-01 | Erba Carlo Spa | Polymer-bound camptothecin derivatives |
US5880131A (en) | 1993-10-20 | 1999-03-09 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
US5965566A (en) * | 1993-10-20 | 1999-10-12 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
JPH09504033A (en) | 1993-10-20 | 1997-04-22 | エンゾン,インコーポレーテッド | 2'- and / or 7-substituted taxoids |
US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5415869A (en) | 1993-11-12 | 1995-05-16 | The Research Foundation Of State University Of New York | Taxol formulation |
US5443953A (en) * | 1993-12-08 | 1995-08-22 | Immunomedics, Inc. | Preparation and use of immunoconjugates |
US5441598A (en) * | 1993-12-16 | 1995-08-15 | Motorola, Inc. | Polishing pad for chemical-mechanical polishing of a semiconductor substrate |
EP0673182B1 (en) * | 1994-03-18 | 2000-03-29 | Lg Electronics Inc. | Method for automatic control of a microwave oven |
US5468754A (en) * | 1994-04-19 | 1995-11-21 | Bionumerik Pharmaceuticals, Inc. | 11,7 substituted camptothecin derivatives and formulations of 11,7 substituted camptothecin derivatives and methods for uses thereof |
US5730990A (en) | 1994-06-24 | 1998-03-24 | Enzon, Inc. | Non-antigenic amine derived polymers and polymer conjugates |
US5629433A (en) * | 1994-07-18 | 1997-05-13 | Hauser, Inc. | Selective process for the deacylation and deacetylation of taxol and taxanes |
US5646159A (en) * | 1994-07-20 | 1997-07-08 | Research Triangle Institute | Water-soluble esters of camptothecin compounds |
JP3770628B2 (en) * | 1994-08-09 | 2006-04-26 | サントリー株式会社 | Prevention and amelioration of medical symptoms through delayed allergic reaction |
US5583153A (en) | 1994-10-06 | 1996-12-10 | Regents Of The University Of California | Use of taxol in the treatment of rheumatoid arthritis |
US6295716B1 (en) | 1994-10-28 | 2001-10-02 | American Superconductor Corporation | Production and processing of (Bi,Pb) SCCO superconductors |
US5633573A (en) * | 1994-11-10 | 1997-05-27 | Duracell, Inc. | Battery pack having a processor controlled battery operating system |
US5783178A (en) * | 1994-11-18 | 1998-07-21 | Supratek Pharma. Inc. | Polymer linked biological agents |
US5489589A (en) | 1994-12-07 | 1996-02-06 | Bristol-Myers Squibb Company | Amino acid derivatives of paclitaxel |
US5580899A (en) * | 1995-01-09 | 1996-12-03 | The Liposome Company, Inc. | Hydrophobic taxane derivatives |
US5736156A (en) * | 1995-03-22 | 1998-04-07 | The Ohio State University | Liposomal anf micellular stabilization of camptothecin drugs |
US5866026A (en) * | 1995-06-01 | 1999-02-02 | Columbia Machine, Inc. | Method and apparatus for accommodating tolerances in a mold for concrete products |
US5801191A (en) * | 1995-06-01 | 1998-09-01 | Biophysica Foundation | Taxoids |
CA2178541C (en) | 1995-06-07 | 2009-11-24 | Neal E. Fearnot | Implantable medical device |
SG50747A1 (en) * | 1995-08-02 | 1998-07-20 | Tanabe Seiyaku Co | Comptothecin derivatives |
US5762909A (en) | 1995-08-31 | 1998-06-09 | General Electric Company | Tumor targeting with polymeric molecules having extended conformation |
US5736129A (en) * | 1995-11-17 | 1998-04-07 | Medenica; Rajko D. | Flow cytometric pharmacosensitivity assay and method of cancer treatment |
CA2192725C (en) * | 1995-12-28 | 2004-04-20 | Kenji Tsujihara | Camptothecin derivatives |
US5776925A (en) | 1996-01-25 | 1998-07-07 | Pharmacyclics, Inc. | Methods for cancer chemosensitization |
US6441025B2 (en) | 1996-03-12 | 2002-08-27 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
CN1304058C (en) | 1996-03-12 | 2007-03-14 | Pg-Txl有限公司 | Water soluble paclitaxel prodrugs |
US5626882A (en) * | 1996-03-15 | 1997-05-06 | Agraquest, Inc. | Method of using EMU oil as an insect repellent |
US6030941A (en) * | 1996-05-01 | 2000-02-29 | Avi Biopharma, Inc. | Polymer composition for delivering substances in living organisms |
US5646506A (en) * | 1996-08-21 | 1997-07-08 | Suzuki; Takeshi | Method of charging a secondary battery and an apparatus therefor |
US5888026A (en) * | 1997-01-24 | 1999-03-30 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Natural Resources | Backfill paste production facility and method and apparatus for producing high density slurry and paste backfills |
US5854006A (en) * | 1997-03-28 | 1998-12-29 | The University Of Virginia | Gamma-glutamyl transpeptidase-specific antibody, prodrugs for the treatment of gamma-glutamyl transpeptidase-expressing tumors, and methods of administration thereof |
US5854382A (en) | 1997-08-18 | 1998-12-29 | Meadox Medicals, Inc. | Bioresorbable compositions for implantable prostheses |
GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
US6011042A (en) * | 1997-10-10 | 2000-01-04 | Enzon, Inc. | Acyl polymeric derivatives of aromatic hydroxyl-containing compounds |
US5960790A (en) * | 1997-12-22 | 1999-10-05 | Rich; Albert Clark | Modular solar energy collection system |
JPH11241027A (en) * | 1998-02-26 | 1999-09-07 | Sony Corp | Polymeric composite material and its production |
US6156017A (en) * | 1998-08-11 | 2000-12-05 | Shieh; Shin Jiu | Cleaning device |
US6218367B1 (en) | 1998-09-15 | 2001-04-17 | Organomed Corporation | Paclitaxel-carbohydrate conjugates: design, synthesis and biological evaluations |
US20010041189A1 (en) | 1999-04-13 | 2001-11-15 | Jingya Xu | Poly(dipeptide) as a drug carrier |
US6191119B1 (en) * | 1999-10-15 | 2001-02-20 | Supergen, Inc. | Combination therapy including 9-nitro-20(S)-camptothecin |
MXPA02009082A (en) | 2000-03-17 | 2003-12-11 | Cell Therapeutics Inc | Polyglutamic acid-camptothecin conjugates and methods of preparation. |
FR2822834B1 (en) * | 2001-04-02 | 2005-02-25 | Flamel Tech Sa | COLLOIDAL SUSPENSION OF NANOPARTICLES BASED ON AMPHIPHILIC COPOLYMERS FOR VECTORIZATION OF ACTIVE INGREDIENTS AND THEIR METHOD OF PREPARATION |
US6837673B2 (en) * | 2002-01-25 | 2005-01-04 | Hitachi, Ltd. | Turbine-unit disassembling method and turbine unit |
-
1998
- 1998-03-30 US US09/050,662 patent/US6441025B2/en not_active Expired - Lifetime
-
1999
- 1999-03-30 AU AU34556/99A patent/AU3455699A/en not_active Abandoned
- 1999-03-30 WO PCT/US1999/006870 patent/WO1999049901A1/en active IP Right Grant
- 1999-03-30 AT AT99916188T patent/ATE304867T1/en active
- 1999-03-30 DE DE69927350T patent/DE69927350T2/en not_active Expired - Lifetime
- 1999-03-30 CA CA2303338A patent/CA2303338C/en not_active Expired - Fee Related
- 1999-03-30 TW TW088104989A patent/TWI246922B/en not_active IP Right Cessation
- 1999-03-30 DK DK99916188T patent/DK1028756T3/en active
- 1999-03-30 EP EP05007529A patent/EP1598081A3/en not_active Withdrawn
- 1999-03-30 EP EP99916188A patent/EP1028756B1/en not_active Expired - Lifetime
- 1999-03-30 TW TW093136237A patent/TWI255183B/en not_active IP Right Cessation
- 1999-03-30 MY MYPI99001207A patent/MY121807A/en unknown
- 1999-03-30 ES ES99916188T patent/ES2249888T3/en not_active Expired - Lifetime
-
2002
- 2002-05-17 US US10/146,809 patent/US6884817B2/en not_active Expired - Lifetime
- 2002-05-24 US US10/153,818 patent/US6515017B1/en not_active Expired - Lifetime
- 2002-09-12 US US10/243,079 patent/US20030114397A1/en not_active Abandoned
- 2002-09-12 US US10/243,046 patent/US20030113335A1/en not_active Abandoned
- 2002-09-12 US US10/243,080 patent/US20030114363A1/en not_active Abandoned
- 2002-09-12 US US10/243,045 patent/US20030114518A1/en not_active Abandoned
- 2002-10-28 US US10/282,570 patent/US20030134793A1/en not_active Abandoned
- 2002-10-28 US US10/282,490 patent/US7135496B2/en not_active Expired - Fee Related
- 2002-11-18 US US10/298,327 patent/US20030130178A1/en not_active Abandoned
- 2002-11-18 US US10/298,375 patent/US20030130341A1/en not_active Abandoned
- 2002-11-18 US US10/298,349 patent/US20030130170A1/en not_active Abandoned
- 2002-11-20 US US10/300,031 patent/US6730699B2/en not_active Expired - Lifetime
- 2002-12-05 US US10/310,331 patent/US20030147807A1/en not_active Abandoned
- 2002-12-05 US US10/310,511 patent/US20030124055A1/en not_active Abandoned
-
2003
- 2003-01-30 US US10/354,431 patent/US7060724B2/en not_active Expired - Fee Related
- 2003-07-14 US US10/620,238 patent/US20040018960A1/en not_active Abandoned
-
2004
- 2004-04-19 US US10/826,302 patent/US20040198638A1/en not_active Abandoned
-
2005
- 2005-10-20 US US11/253,810 patent/US20060111273A1/en not_active Abandoned
- 2005-11-10 CY CY20051101376T patent/CY1105547T1/en unknown
- 2005-11-23 US US11/285,392 patent/US20060135404A1/en not_active Abandoned
-
2006
- 2006-08-31 US US11/513,390 patent/US7384977B2/en not_active Expired - Fee Related
-
2007
- 2007-10-29 US US11/927,392 patent/US20080153865A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5473055A (en) * | 1992-06-19 | 1995-12-05 | Farmitalia Carlo Erba S.R.L. | Polymer-bound paclitaxel derivatives |
US5730968A (en) * | 1994-03-31 | 1998-03-24 | Sterling Winthrop Inc. | Segmented chelating polymers as imaging and therapeutic agents |
US5626862A (en) * | 1994-08-02 | 1997-05-06 | Massachusetts Institute Of Technology | Controlled local delivery of chemotherapeutic agents for treating solid tumors |
Non-Patent Citations (1)
Title |
---|
LI CHUN ET AL.: "WATER-SOLUBLE POLYGLUTAMIC ACID-PACLITAXEL CONJUGATE (PGA-PACLITAXEL) ANTITUMOR REFRESSION IN RATS BRAEING 13762 MAMMARYCARCINOMA", PHARMACEUTICAL RESEARCH, SPRINGER NEW YORK LLC, US, vol. 13, no. 09, 1 September 1996 (1996-09-01), US, pages S368, XP002921299, ISSN: 0724-8741, DOI: 10.1023/A:1016032207246 * |
Cited By (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7384977B2 (en) | 1996-03-12 | 2008-06-10 | Pg-Txl Company, L.P. | Water soluble paclitaxel prodrugs |
US7060724B2 (en) | 1996-03-12 | 2006-06-13 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
US7135496B2 (en) | 1996-03-12 | 2006-11-14 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
US7399860B2 (en) | 1999-10-12 | 2008-07-15 | Cell Therapeutics Inc. | Manufacture of polyglutamate-therapeutic agent conjugates |
AU781735B2 (en) * | 1999-10-12 | 2005-06-09 | Cell Therapeutics, Inc. | Manufacture of polyglutamate-therapeutic agent conjugates |
JP2003511423A (en) * | 1999-10-12 | 2003-03-25 | セル・セラピューティックス・インコーポレーテッド | Preparation of polyglutamate-therapeutic drug conjugate |
WO2001026693A2 (en) * | 1999-10-12 | 2001-04-19 | Cell Therapeutics, Inc. | Manufacture of polyglutamate-therapeutic agent conjugates |
WO2001026693A3 (en) * | 1999-10-12 | 2001-12-27 | Cell Therapeutics Inc | Manufacture of polyglutamate-therapeutic agent conjugates |
SG147286A1 (en) * | 1999-10-12 | 2008-11-28 | Cell Therapeutics Inc | Manufacture of polyglumate-therapeutic agent conjugates |
EP1466627A1 (en) | 1999-10-12 | 2004-10-13 | Cell Therapeutics, Inc. | Polyglutamate camptothecin conjugates |
US7632484B2 (en) | 1999-10-25 | 2009-12-15 | Board Of Regents, The University Of Texas System | Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging |
US7067111B1 (en) | 1999-10-25 | 2006-06-27 | Board Of Regents, University Of Texas System | Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging |
US7223380B2 (en) | 1999-10-25 | 2007-05-29 | Board Of Regents, The University Of Texas System | Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging |
US7229604B2 (en) | 1999-10-25 | 2007-06-12 | Board Of Regents, The University Of Texas System | Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging |
EP1235598A2 (en) * | 1999-11-12 | 2002-09-04 | Angiotech Pharmaceuticals, Inc. | Compositions of a combination of radioactive therapy and cell-cycle inhibitors |
WO2001070275A3 (en) * | 2000-03-17 | 2002-01-03 | Cell Therapeutics Inc | Polyglutamic acid-camptothecin conjugates and methods of preparation |
US7173041B2 (en) | 2000-03-17 | 2007-02-06 | Cell Therapeutics Inc. | Polyglutamic acid-camptothecin conjugates and methods of preparation |
US7153864B2 (en) | 2000-03-17 | 2006-12-26 | Cell Therapeutics Inc. | Polyglutamic acid-camptothecin conjugates and methods of preparation |
WO2001070275A2 (en) * | 2000-03-17 | 2001-09-27 | Cell Therapeutics, Inc. | Polyglutamic acid-camptothecin conjugates and methods of preparation |
US6869973B2 (en) | 2000-06-22 | 2005-03-22 | Nitromed, Inc. | Nitrosated and nitrosylated taxanes, compositions and methods of use |
US6656966B2 (en) | 2000-06-22 | 2003-12-02 | Nitromed, Inc. | Nitrosated and nitrosylated taxanes, compositions and methods of use |
EP2080511A2 (en) * | 2000-08-22 | 2009-07-22 | Shire LLC | Active agent delivery systems and methods for protecting and administering active agents |
US7427600B2 (en) | 2000-08-22 | 2008-09-23 | Shire Llc | Active agent delivery systems and methods for protecting and administering active agents |
EP1311242A4 (en) * | 2000-08-22 | 2005-09-28 | New River Pharmaceuticals Inc | Active agent delivery systems and methods for protecting and administering active agents |
EP2080511A3 (en) * | 2000-08-22 | 2009-09-30 | Shire LLC | Active agent delivery systems and methods for protecting and administering active agents |
EP1311242A1 (en) * | 2000-08-22 | 2003-05-21 | New River Pharmaceuticals, Inc. | Active agent delivery systems and methods for protecting and administering active agents |
WO2003026718A1 (en) * | 2000-10-31 | 2003-04-03 | Cook Incorporated | Coated implantable medical device |
US6918927B2 (en) | 2000-10-31 | 2005-07-19 | Cook Incorporated | Coated implantable medical device |
EP1401374A1 (en) * | 2000-11-14 | 2004-03-31 | New River Pharmaceuticals Inc. | A novel pharmaceutical compound containing abacavir sulfate and methods of making and using same |
AU2001298033B2 (en) * | 2000-11-14 | 2007-08-09 | Shire Llc | A novel pharmaceutical compound containing abacavir sulfate and methods of making and using same |
EP1401374A4 (en) * | 2000-11-14 | 2006-02-15 | New River Pharmaceuticals Inc | A novel pharmaceutical compound containing abacavir sulfate and methods of making and using same |
US7261875B2 (en) | 2001-12-21 | 2007-08-28 | Board Of Regents, The University Of Texas System | Dendritic poly (amino acid) carriers and methods of use |
WO2004011034A1 (en) * | 2002-07-31 | 2004-02-05 | General Electric Company | Conjugated lysine copolymers for drug delivery and imaging |
EP1475105A1 (en) * | 2003-05-09 | 2004-11-10 | Schering AG | Bone localising radiopharmaceutical and tubulin-interacting compound combinatorial radiotherapy |
WO2004098651A3 (en) * | 2003-05-09 | 2005-04-07 | Schering Ag | Bone localising radiopharmaceutical and tubulin-interacting compound combinatorial radiotherapy |
US9050378B2 (en) | 2003-12-10 | 2015-06-09 | Board Of Regents, The University Of Texas System | N2S2 chelate-targeting ligand conjugates |
WO2005079861A3 (en) * | 2004-02-13 | 2007-03-15 | Safeway Invest Ltd | Polymeric water soluble prodrugs |
WO2005079861A2 (en) * | 2004-02-13 | 2005-09-01 | Safeway Investments Ltd. | Polymeric water soluble prodrugs |
CN100361985C (en) * | 2004-10-26 | 2008-01-16 | 中国科学院长春应用化学研究所 | Paclitaxol predrug of biodegradable polymer and its synthesis method |
US9938331B2 (en) | 2005-09-27 | 2018-04-10 | Amunix Operating Inc. | Biologically active proteins having increased in vivo and/or in vitro stability |
US7846445B2 (en) | 2005-09-27 | 2010-12-07 | Amunix Operating, Inc. | Methods for production of unstructured recombinant polymers and uses thereof |
US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
US8492530B2 (en) | 2005-09-27 | 2013-07-23 | Amunix Operating Inc. | Unstructured recombinant polymers and compositions comprising same |
US9855338B2 (en) | 2005-12-05 | 2018-01-02 | Nitto Denko Corporation | Polyglutamate-amino acid conjugates and methods |
CN100431610C (en) * | 2006-01-24 | 2008-11-12 | 中国科学院长春应用化学研究所 | Amphiphilic tri-block copolymer-paclitaxel bonded drug and preparation method thereof |
US10814013B2 (en) | 2006-10-05 | 2020-10-27 | The Board Of Regents Of The University Of Texas System | Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications |
US10925977B2 (en) | 2006-10-05 | 2021-02-23 | Ceil>Point, LLC | Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications |
US8933197B2 (en) | 2007-08-15 | 2015-01-13 | Amunix Operating Inc. | Compositions comprising modified biologically active polypeptides |
WO2009076272A3 (en) * | 2007-12-07 | 2010-04-22 | Boston Scientific Scimed, Inc. | Drug coated stent with endosome-disrupting conjugate |
WO2009076272A2 (en) * | 2007-12-07 | 2009-06-18 | Boston Scientific Scimed, Inc. | Drug coated stent with endosome-disrupting conjugate |
US10961287B2 (en) | 2009-02-03 | 2021-03-30 | Amunix Pharmaceuticals, Inc | Extended recombinant polypeptides and compositions comprising same |
US8680050B2 (en) | 2009-02-03 | 2014-03-25 | Amunix Operating Inc. | Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same |
US8957021B2 (en) | 2009-02-03 | 2015-02-17 | Amunix Operating Inc. | Glucose-regulating polypeptides and methods of making and using same |
US9168312B2 (en) | 2009-02-03 | 2015-10-27 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
US8716448B2 (en) | 2009-02-03 | 2014-05-06 | Amunix Operating Inc. | Coagulation factor VII compositions and methods of making and using same |
US9371369B2 (en) | 2009-02-03 | 2016-06-21 | Amunix Operating Inc. | Extended recombinant polypeptides and compositions comprising same |
US8703717B2 (en) | 2009-02-03 | 2014-04-22 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
US8673860B2 (en) | 2009-02-03 | 2014-03-18 | Amunix Operating Inc. | Extended recombinant polypeptides and compositions comprising same |
US9926351B2 (en) | 2009-02-03 | 2018-03-27 | Amunix Operating Inc. | Extended recombinant polypeptides and compositions comprising same |
US10000543B2 (en) | 2009-06-08 | 2018-06-19 | Amunix Operating Inc. | Glucose-regulating polypeptides and methods of making and using same |
US9540430B2 (en) | 2009-06-08 | 2017-01-10 | Amunix Operating Inc. | Glucose-regulating polypeptides and methods of making and using same |
US9849188B2 (en) | 2009-06-08 | 2017-12-26 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
US9062299B2 (en) | 2009-08-24 | 2015-06-23 | Amunix Operating Inc. | Coagulation factor IX compositions and methods of making and using same |
US9758776B2 (en) | 2009-08-24 | 2017-09-12 | Amunix Operating Inc. | Coagulation factor IX compositions and methods of making and using same |
US9376672B2 (en) | 2009-08-24 | 2016-06-28 | Amunix Operating Inc. | Coagulation factor IX compositions and methods of making and using same |
US8557961B2 (en) | 2010-04-02 | 2013-10-15 | Amunix Operating Inc. | Alpha 1-antitrypsin compositions and methods of making and using same |
EP3372617A2 (en) | 2010-04-02 | 2018-09-12 | Amunix Operating Inc. | Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same |
US10870874B2 (en) | 2010-04-02 | 2020-12-22 | Amunix Pharmaceuticals, Inc. | Binding fusion proteins, binding fusion protein-drug conjugates, XTEN-drug conjugates and methods of making and using same |
US9976166B2 (en) | 2010-04-02 | 2018-05-22 | Amunix Operating Inc. | Binding fusion proteins, binding fusion protein-drug conjugates, XTEN-drug conjugates and methods of making and using same |
US9249211B2 (en) | 2010-04-02 | 2016-02-02 | Amunix Operating Inc. | Binding fusion proteins, binding fusion protein-drug conjugates, XTEN-drug conjugates and methods of making and using same |
US10370430B2 (en) | 2012-02-15 | 2019-08-06 | Bioverativ Therapeutics Inc. | Recombinant factor VIII proteins |
US10421798B2 (en) | 2012-02-15 | 2019-09-24 | Bioverativ Therapeutics Inc. | Factor VIII compositions and methods of making and using same |
US11685771B2 (en) | 2012-02-15 | 2023-06-27 | Bioverativ Therapeutics Inc. | Recombinant factor VIII proteins |
US10172953B2 (en) | 2012-02-27 | 2019-01-08 | Amunix Operating Inc. | XTEN conjugate compositions and methods of making same |
US10953073B2 (en) | 2012-02-27 | 2021-03-23 | Amunix Pharmaceuticals, Inc. | XTEN conjugate compositions and methods of making same |
US10548953B2 (en) | 2013-08-14 | 2020-02-04 | Bioverativ Therapeutics Inc. | Factor VIII-XTEN fusions and uses thereof |
US10745680B2 (en) | 2015-08-03 | 2020-08-18 | Bioverativ Therapeutics Inc. | Factor IX fusion proteins and methods of making and using same |
US11713358B2 (en) | 2015-08-28 | 2023-08-01 | Amunix Pharmaceuticals, Inc. | Chimeric polypeptide assembly and methods of making and using the same |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6515017B1 (en) | Water soluble paclitaxel derivatives | |
AU735900B2 (en) | Water soluble paclitaxel prodrugs | |
JP2001288097A (en) | Water-soluble paclitaxel derivative | |
Copie et al. | Water soluble paclitaxel prodrugs | |
MXPA98007442A (en) | Soluble paclitaxel profarmacos in a |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2303338 Country of ref document: CA Ref country code: CA Ref document number: 2303338 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999916188 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1999916188 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09530601 Country of ref document: US |
|
WWG | Wipo information: grant in national office |
Ref document number: 1999916188 Country of ref document: EP |